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Introduction: Comprehensive pain assessment depends on the use of psychometrically valid 
patient-reported outcome measures (PROMs). The Brief Pain Inventory-Short Form (BPI-SF) 
and Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2) are general-use 
multidimensional pain assessment tools commonly used in musculoskeletal conditions. 
Understanding all relevant measurement properties supports stronger decisions about PROMs. 
Thesis Objectives: The overarching objective of this thesis was to determine the sufficiency 
of measurement evidence backing the use of the BPI-SF and SF-MPQ-2 in musculoskeletal 
conditions. Specifically, a systematic review was conducted to locate, summarize and 
compare the quality and content of psychometric evidence backing the BPI-SF and SF-MPQ-
2 in musculoskeletal conditions. Based on this review, the gap in evidence regarding the 
reliability and agreement properties (reproducibility) of SF-MPQ-2 was examined among 
patients with musculoskeletal shoulder pain. 
Methods: For the systematic review, we searched four databases to identify relevant citations. 
Two reviewers independently screened, extracted and appraised (using MacDermid and 
COSMIN guidelines) all psychometric reports on both tools in musculoskeletal conditions. To 
determine the SF-MPQ-2 reproducibility, a convenience sample of adults diagnosed with 
musculoskeletal shoulder pain (baseline, n=195; test-retest, n=48) completed the SF-MPQ-2 
twice. Cronbach alpha (α), intraclass correlations coefficient (ICC2,1), agreement parameters 
(SEM, MDC) and Bland-Altman plots were assessed. 
Results: High quality evidence indicated both tools have high internal consistency (α = 0.83-
0.96); and that they are moderately related (r = 0.3-0.69) to other health-related outcome 
measures. More studies of better quality have evaluated the BPI-SF responsiveness (n=5), 
retest reliability (n=3), known group validity (n=2) and structural validity (n=3), compared to 
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the SF-MPQ-2. Our analysis of the SF-MPQ-2 reproducibility established internal consistency 
as satisfactory (α, 0.83-0.95), relative reliability as good (neuropathic, intermittent, and 
affective subscales: 1CC2,1= 0.78 - 0.88) to excellent (total and continuous subscale scores: 
1CC2,1= 0.92 - 0.95). Agreement was within acceptable limits and there was no evidence of 
systematic bias. 
Conclusion: A greater volume of evidence of better quality currently supports the BPI-SF 
although emerging evidence suggest the SF-MPQ-2 has excellent reliability and agreement 
properties when used to assess adults with musculoskeletal shoulder pain. Direct comparisons 
of the two scales in different contexts are needed. 
Keywords: Brief Pain Inventory; Musculoskeletal Conditions; McGill Pain Questionnaire; 



















What is the problem? Musculoskeletal  (MSK) refers to anything related to our muscles, 
tendons, joints and connective tissue. Pain that comes from any of these tissues is called MSK 
pain. MSK pain is one of the most common reasons people seek treatment from a doctor or 
therapist, so the better we understand this pain, the better decisions we can make about 
treatment. An important way of measuring MSK pain is by asking the person to give ratings 
for different aspects of their pain using tools called patient-reported outcome measures (or 
PROMS for short). Health care providers use PROMs for pain assessment because they are 
simple and affordable.  But more important, they give accurate scores that help monitor 
treatment progress from the person’s own view. Researchers and health care providers need to 
know which tools are best for MSK pain, especially when they are used to assess more than 
one condition, like fractures and tendonitis. 
Study question: The key question in my thesis work was: is there enough good evidence  that 
researchers and health care providers can feel confident using the Brief Pain Inventory Short-
Form (BPI-SF) and Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2) for 
measuring MSK pain? 
How did we study the problem? We did a careful search of online libraries of health science 
research to find every study we could that told us about both tools. We recorded all the key 
information about how well they measured MSK pain. Then, we assessed and compared the 
quality of these studies, so we knew what information was best. In our second study, we 
checked if the SF-MPQ-2 gave us the same (reliable) scores when it was used by patients 
coming to see a doctor because of shoulder pain at two different times.  
What did we learn? After all these studies, we concluded that the BPI-SF currently has more 
good quality evidence backing its use in MSK condition than the SF-MPQ-2. We are also 
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confident that SF-MPQ-2 will probably be a good tool for measuring MSK shoulder pain 
since it yields consistent scores from our evaluation.  
What do we still not know? Researchers and health care providers who want to use these 
tools should be aware that they are not yet the ‘gold standard’. More research is needed to 
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Overview of Musculoskeletal Disorders 
‘Musculoskeletal disorders’ (MSDs), as a term, describes a vast number of 
inflammatory and degenerative conditions affecting the muscles, tendons, ligaments, joints, 
peripheral nerves, and supporting blood vessels (1). More than 291 pathologies (2) have been 
defined as MSDs, and may include conditions with a) unambiguous pathophysiology such as, 
tendon inflammations (e.g. tenosynovitis, epicondylitis, bursitis), nerve compression disorders 
(e.g. carpal tunnel syndrome, sciatica), and osteoarthritis, or b) conditions with ambiguous or 
less standardized pathophysiology (e.g. myalgia, low back pain) and generalized body pain of 
unknown cause (1,3). MSDs predominantly affect the low back, neck, shoulder, forearm, 
hand, and the lower extremity (1,4). 
MSDs are the most common cause of long-term pain and disability (3,5,6). MSDs 
impact negatively on an individual’s level of participation, quality of life, social, 
psychological and economic well-being (6,7). The prevalence of MSDs is high and is 
expected to continue to increase for several reasons including greater rates of obesity, 
sedentary lifestyle, and the growing ageing population (3). MSDs currently account for 21.3% 
of the total years lived with disability (YLDs) and globally represent the 4th largest health 
burden (8). Prevalence rates are higher in developed countries than in developing countries. 
For instance, at any one time, joint pain, swelling, or limitation of movement will affect no 
less than 30% of American adults in their life time and represent the leading cause of 
disability among adults within or below 45-year-old  (6). In Ontario Canada, MSDs account 
for 40% of all chronic conditions, 54% of all long-term disabilities and 24% of all restricted 
activity days (9). MSDs such as rheumatoid arthritis, osteoarthritis, osteoporosis, spinal 
disorders and major limb traumas come with the greatest financial consequence on the 
individual and society (8). In Canada, treatment and management of MSDs directly accounts 





and professional bills, while MSDs indirectly cost 25 billion dollars from loss to 
disability/profitable work hours and premature death (7). Recent reports for the United States 
indicate MSDs cost over 125 billion dollars per annum directly and indirectly. Indeed, MSDs 
are pervasive burdens with influence reaching all ages, walks of life, countries and regions. 
Overview of Shoulder Pain 
 Shoulder pain, the third most common musculoskeletal complain after back and neck 
pain, originates from different problems affecting the shoulder structures (10–12). As the most 
mobile joint of the body, the shoulder is at high risk of instability and pain. Also, the shoulder 
links the upper extremity to the thorax; hence, tissues including muscles, tendons, and major 
neurovascular structures surrounding the shoulder indirectly become potential sources of 
referred pain (12). Examples of conditions affecting the shoulder directly include: (a) Rotator 
Cuff Disorders (RCDs): a group of disorders including rotator cuff tendinopathy, 
impingement, sub-acromial bursitis, rotator cuff tears; (b) Glenohumeral Disorders: capsulitis 
(“frozen shoulder”), arthritis; (c) Acromioclavicular Diseases; (d) Infection; and (e) Traumatic 
Dislocation. Of these conditions, RCDs are the most common pathology affecting the 
shoulder joint. Other conditions that can affect the shoulder indirectly include: (a) Neck Pain; 
(b) Myocardial Ischemia; (c) Referred Diaphragmatic Pain; (d) Polymyalgia Rheumatica; and 
(e) Malignancy i.e. apical lung cancers or metastases (11).  
 A review of shoulder pain/complaints prevalence studies till the year 2001(13) noted 
substantial variation in ranges across study reports: point prevalence ranged from 7-27% 
(adults > 70 years) and 13.2 – 26% (adults < 70years). The annual prevalence of shoulder 
pain/complaints ranged from 5 – 47% (13); another review estimated prevalence of shoulder 
complaints at 50% in the general population (14). The annual incidence of shoulder 
complaints was 7% in the general population (14) but varied across different age groups at 





Leclerc et al. (15) has summarized risk factors for shoulder pain as a mix of personal 
(e.g. age and gender), occupational factors (skilled, semi-skilled or unskilled jobs), lifestyle 
behaviors (e.g. physical inactivity) and existing comorbidities (e.g. depression, heart and sleep 
conditions, and obesity). While the risk of shoulder pain increases with age (15), being a 
female (16) and having a long history of smoking are other risk factors for shoulder pain (17). 
Individuals who engaged or are engaging in an unskilled job that requires the constant use of 
their upper limb are more likely to report shoulder pain than those in skilled and semi-skilled 
jobs who do not use their upper limb repetitively while performing their job responsibilities 
(18). Physically inactive persons are also highly predisposed to shoulder pain (19). Moreover, 
the presence of mental/psychological comorbidities like depression and anxiety (20), 
undergoing a previous shoulder surgery, or even experiencing a past injury/dislocation on the 
shoulder can increase the risk of persistent shoulder pain (15).  
Musculoskeletal Pain as a Multidimensional Construct 
The International Association for the Study of Pain (IASP) describes pain as: “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage” (21). Pain is not only the most recurrent 
symptom in musculoskeletal disorders but also accounts for most of the accompanying burden 
of disease (22). Although pain was initially perceived as a unidimensional construct with a 
resultant emphasis on capturing intensity, overwhelming evidence has established the 
multidimensional nature of pain (23,24). For instance, Melzack and Casey (25) hypothesized 
three dimensions, including: the sensory–discriminative, motivational–affective and 
cognitive–evaluative. The experience of pain perception is the confluence of six dimensions: 
physiologic, sensory, affective, cognitive, behavioral and socio-cultural (26,27). Since pain is 





multidimensional patient-reported outcome measures (PROMs) that can adequately capture 
and quantify how pain impacts on different domains. 
Patient-reported Outcome Measures (PROMs) 
Patient-reported outcome measures (PROMs) are standardized, validated 
questionnaires completed by patients to measure their perceptions of their own functional 
status and wellbeing (28). Although initially developed for monitoring treatment effectiveness 
in clinical trials, PROMs are now used to also evaluate the patients view about their 
symptoms, functional status, treatment and other health-related qualities of life (28–30). In the 
past two decades, the importance of PROMs has been more recognized and widely accepted 
in health care practice. This is due to a shift in understanding that the patient’s perspective 
about their health is genuine, and as valid as findings obtained from conventional biomedical 
clinical tests, lab results, and the clinicians’ view (29,31). 
Types of PROMs and their Advantages. 
PROMs can be classified into seven main types (29). The first is disease-specific tools 
e.g. Western Ontario Rotator Cuff index (32): they focus on a specific disease, and are likely 
more sensitive to change, and appreciated by patients. Secondly, site or region-specific tools 
e.g. Knee injury and Osteoarthritis Outcome Score (33) or Shoulder Pain and Disability Index 
(34) can be used to evaluate conditions affecting the region of interest, often irrespective of 
the origin of pathology. Third are dimension-specific tools e.g. the Brief Pain Inventory-
Short Form (BPI-SF) (35) or Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-
2) (36): they provide the advantages of a thorough and exhaustive assessment of a health 
domain and can be compared across conditions. Fourth, generic tools e.g. the Medical 
Outcome Study 36-Item Short-Form Health Survey (37) can be applied in multiple conditions 
when disease-specific assessments are not available for evaluation. Fifth, summary items are 





Global Rating of Change scales (38). Sixth, individualized PROMs e.g. Patient-specific 
Functional scale (39): respondents using this tool are not bounded to questions but are free to 
define their concerns or goals for treatment. Seventh, utility tools e.g. EuroQoL EQ-5D (40), 
allow respondents to quantify their preferences and values regarding their overall health 
status. 
Psychometric Properties to consider when selecting PROMs.  
Many outcome tools can be used for pain assessment in musculoskeletal conditions 
and selecting the most appropriate outcome measures for clinical or research purposes has 
become a difficult task that requires good understanding of psychometric properties, in 
addition to other factors (29,41,42). Some of the important psychometric properties that need 
to be considered when making decisions to select a PROM includes: 
1. Validity, the level to which a tool measures the intended construct(s) (29,43), should 
be satisfactorily established for a tool to be considered for evaluation purposes. Ways of 
estimating validity includes investigating: (a) convergent and discriminative validity, where a 
clear hypothesis must be provided a priori (44,45); (b) criterion validity, where comparison is 
made against an established gold standard (42,46); and (c) structural validity using Rasch 
modelling or factor analysis to examine the dimensionality of multidimensional tools (41,42).  
Content validity is the most foundational type of validity since without it, other 
validity indices have little value. It is the degree to which the content of a PROM instrument 
reflects the construct to be measured (43) and as such, describes how representative the items 
of a PROM reflect the patient’s perspective under evaluation. Face validity can also be 
evaluated as a step toward establishing content validity. It entails synthesizing the impression 
of experts and/or patients (tool users) on the adequacy of tool (41,47). An instrument’s 
content must adequately reflect what it is expected to evaluate before it should be considered 





psychometric properties because a tool with unrepresentative items does not merit any further 
evaluation (29,47). 
2. Reliability, the degree to which the measurement is free from error (43), describes the 
reproducibility and internal consistency of a PROM instrument. Reproducibility is a critical 
measurement property that needs to be determined, especially, for all pain assessment tools. It 
measures the degree to which repeated measurements in stable respondents provide similar 
results (48–50) and as such, precedes evaluation of responsiveness or validity. Good evidence 
demonstrating relative and absolute reliability of a tool supports reproducibility; however, 
both forms of reliability focus on two different questions (48,51,52).  
Absolute reliability (agreement) examines how closely related the scores from 
repeated measurement are comparable - that is, the more closely related, the higher the 
reliability, which substantiates the evaluative ability a tool. Methods examining standard error 
of the measurement (SEM) and minimal detectable change (MDC), and inspecting the 
distribution of scores on Bland-Altman plots provide evidence in support of a tool’s absolute 
reliability (48,49). On the other hand, relative reliability is the degree to which individuals 
maintain their position in a sample over repeated measurements (48,49,51). The intraclass 
correlation coefficient (a unitless measure with magnitude ranging from 0 (poor) to 1 (very 
good) is the most accepted means of measuring relative reliability for ratio or interval scale 
scores. Higher ICC scores support the ability of a tool to discriminate between subjects 
regardless of measurement error (51,53,54).  
Test-retest reliability is assessed by testing participants on repeated occasions (55). 
The PROM should be administered repeatedly within in a short enough time interval that 
ensures patients stability yet long enough time interval that avoids learning or memory effects. 
Internal consistency, measured using Cronbach’s alpha, is a weaker form of assessment that is 





3. Responsiveness, the ability of a PROM to evaluate change over time in the construct 
to be measured (43), refers to an instruments ability to detect clinically relevant change. 
Evaluative instruments, like pain assessment tools, are expected to be able to determine the 
presence or absence of change in status following intervention. Some of the acceptable 
statistical approaches utilized for determining a tool’s level of responsiveness include: (a) 
calculating the area under the curve (AUC) using the Receiver Operator Curve (ROC curve), 
(b) estimating the standardize response mean (SRM) or effect sizes and, (c) estimating the 
level of correlation with similar outcomes (44,58). Well-defined hypotheses with magnitude 
and direction of change should always be provided while considering the expected effect of 
administering or withholding an intervention (44,45,59). Statistical methods like the use of the 
paired T-test for significant differences between groups or Guyatt’s responsiveness ratio (60) 
should not be used as indicators of responsiveness (58). 
4. Interpretability, the degree to which one can assign qualitative meaning—that is, 
clinical or commonly understood connotations—to an instrument's quantitative scores or 
change in scores (43), is often established by estimating the minimal clinically important 
difference (MCID) score of the tool. Interpretability makes an instrument easy to use and 
understand in clinical practice and assists with classification and prediction. 
Systematic Reviews of Measurement Studies 
Systematic reviews of measurement studies involve identifying, extracting, critically 
appraising and comparing ‘contextual’ evidence from the literature on a tool’s measurement 
properties (61). Evidence from systematic reviews informs decisions made for or against a 
tool and instill user’s confidence in the tool’s performance. Robust systematic reviews of 
measurement studies rely heavily on critical appraisals to authenticate and synthesize the 
quality of evidence supporting PROMs measurement properties. Critical appraisals often 





responsiveness, etc.) against established standards, and evaluating the methodological quality 
of the study for bias (risk of bias). In some critical appraisal tools, the feasibility/usability of a 
tool, the administration burden and response burden are examined as part of the appraisal 
process. Two popular critical appraisal tools used in measurement studies are: (a) The 
(COnsensus-based Standards for the selection of health status Measurement INstruments) 
(COSMIN) Methodology, which comprises the risk of bias (44,45), quality citeria checklist 
(44,46,49) and the modified Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) (44) and, (b) MacDermid’s measurement studies quality assessment 
checklist (41). While complimentary, they have individual strengths and weakness which need 
to be appreciated. 
Strengths and Limitations of the COSMIN Methodology  
One of the main advantages of the COSMIN methodology lies in its standardized 
definition of measurement properties which guarantees less confusion when extracting 
evidence as described by reporting authors. Also, the COSMIN examines risk of bias per 
report of measurement properties. Therefore, a poor outcome for reporting of one 
measurement property does not necessarily impact on the rating of other reports in the same 
article because each report is treated as a ‘stand-alone’ study. Finally, a comprehensive user’s 
manual (44) is available for reviewers to consult which decreases subjectivity. However, one 
disadvantage of the COSMIN method is that inexperienced users will find it difficult and 
confusing to synthesize and complete all stages of the critical appraisal involving completing 
the risk of bias, quality criteria checklist and Modified GRADE level of evidence 
determination. Further, some of the criterion are quite arbitrary: for instance, a sample of 50-
100 subjects is needed for a study to be rated adequate in reliability assessment, even though 





imprecision are also included as bias criterion. This can have a major impact since it is the 
lowest rating in a section that is selected as the overall rating.   
Strengths and Limitations of the MacDermid’s Appraisal Method 
MacDermid’s tool is focused on overall study design and quality, not the bias 
associated with individual measurement properties. The scaling is numbered, and a total sum 
can be generated which makes it easy for users to conclude on the quality of studies. This 
attribute allows for identification of common design flaws in the individual studies. However, 
the weight apportioned to quality indicators is arbitrary and does not necessarily reflect the 
impact of potential sources of bias. Further, the focus on study design, rather than individual 
measurement properties, does not directly align with the information needed to make 
decisions about the adequacy of individual measurement properties. In addition, more training 
may be required to resolve complexity or sources of disagreement between raters from the 
absence of standardized definitions of measurement properties. As a quality tool, it does not 
focus on assessing risk of bias. Quality and risk of bias are related but separate constructs. 
The Brief Pain Inventory-Short Form (BPI-SF): History, Content Structure and 
Advantages 
The Brief Pain Inventory, formerly the Wisconsin Brief Pain Questionnaire (62,63), 
was initially developed to provide a simple but comprehensive outcome tool for monitoring 
analgesic effect in cancer pain management, epidemiological studies and research. Early 
versions were developed with sponsorship of the National Cancer Institute (NCI) and the 
Cancer Unit of the World Health Organization (WHO) (63). The Brief Pain Inventory has 
undergone series of transformations to improve its structure, including, the addition of the 
‘least pain item’, and reducing the number of items in its long version - to decrease 





short version, commonly referred to as the Brief Pain Inventory, is employed for pain 
assessment in conditions including musculoskeletal disorders (63). 
The content structure of the BPI-SF is based on Beecher’s definition of pain 
dimensionality as ‘sensory’ and ‘reactive’(64). The sensory dimension of the tool evaluates 
how pain severity/intensity fluctuates on four items: pain at its - ‘worst’, ‘least’, ‘on average’ 
and ‘now’. The reactive dimension of the tool evaluates how responders perceive pain 
interference in two sub-dimensions: (a) an activity sub-dimension consisting of 3 items: 
‘work’, ‘general activity’ and ‘walking’, and (b) an affective sub-dimension consisting of 3 
items: ‘relations with others’, ‘enjoyment of life’, and ‘mood’. One item, ‘pain interference 
with sleep’, stands alone and can be influenced by both sub-dimensions (63). 
As the name suggests, the greatest advantage/strength of the BPI-SF is its simplicity 
and brevity: it takes 5-minutes to complete, yet it captures pain comprehensively. Also, the 
BPI-SF evaluates pain ‘interference’, uniquely, with items easily appreciated by patients: 
hence, the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials 
(IMMPACT) group has recommended its use in all chronic pain-related clinical trials (65). 
Finally, multiple language translations (63), based on standard translation processes, are 
available for the BPI-SF which encourages its global use. 
   The Revised Short McGill Pain Questionnaire-2 (SF-MPQ-2): History, Content 
Structure and Advantages 
  The Revised Short McGill Pain Questionnaire Version-2 was developed about a 
decade ago (1st January, 2019) after Dworkin and his team noted the absence of a single tool 
for neuropathic and non-neuropathic pain assessment (36). The previous Short McGill Pain 
Questionnaire was then expanded to the current Revised Short McGill Pain Questionnaire 
Version-2, to be able to simultaneously evaluate and/or discriminate neuropathic and non-





The content structure of the expanded SF-MPQ-2 consist of 22 items: 15 items of 
which were retained from the former version, the Short McGill Pain Questionnaire (36). The 7 
new items added comprise the neuropathic subscale and were selected based on the 
researchers experience and the results of focus groups with chronic pain patients (36). The SF-
MPQ-2 evaluates 2 dimensions of pain: (a) sensory (pain quality and intensity) and, (b) an 
affective dimension (emotional experience of pain). Aside its evaluative properties, it has a 
high discriminative property to distinguish different pain types/qualities. Its 22-items 
distinguish pain into 4 categories: (a) continuous (throbbing pain, cramping pain, gnawing 
pain, aching pain, heavy pain, and tender); (b) neuropathic (hot-burning pain, cold-freezing 
pain, pain caused by light touch, itching, tingling or pins and needles, and numbness); (c) 
affective (tiring-exhausting, sickening, fearful, punishing-cruel), and (d) intermittent (shooting 
pain, stabbing pain, sharp pain, splitting pain, electric-shock pain, piercing).  
As its strengths, the SF-MPQ-2 does not only assess pain intensity but can also be 
used to distinguish pain according to its source. This makes it very useful for pain assessment 
when there is need to be sure of the mechanism of pain (nociceptive or neuropathic), or when 
there is need to quantify mixed (both neuropathic and nociceptive) pain experiences. On the 
down side, some of the SF-MPQ-2 pain descriptors are difficult to appreciate by patients 
(66,67). Also, 22 items in one questionnaire may be perceived as too long and burdensome to 
complete (66,67). Finally, although the Mapi Research Trust has provided computerized 
translations of the SF-MPQ-2, they are not based on standardized cross-cultural translations 
involving forward and backward translation processes. 
Current Gap in the Literature 
The main objective of this thesis was to explain the sufficiency of measurement 
evidence backing the use of the Brief Pain Inventory- Short Form and Revised Short McGill 





are used frequently for musculoskeletal pain assessment both in the clinical and research 
setting, however, no single study has synthesized the scope of evidence supporting their 
measurement properties for use in MSK conditions. MSK conditions are common but diverse. 
Clearly understanding the measurement properties backing outcome measures can inform 
users choice. Hence, the absence of a comprehensive review of the evidence suggest selection 
by researchers/clinicians is based on reports obtained from single studies, colleagues or peers’ 
recommendations, easy access to the tools, high recognition or even the appearance of their 
items/face validity (68). However, we know that comprehensive pain assessment depends on 
the use of tools with proven context-specific evidence backing their measurement properties, 
because only valid tools yield dependable scores (41,42,44–46,59,69). Therefore, 
systematically reviewing the literature to determine the sufficiency of evidence for 
measurement properties underpinning the use of the BPI-SF and SF-MPQ-2 in MSK 
conditions is overdue and necessary. 
The two research questions guiding this dissertation were as follows: 
1. What is the quality and content of measurement evidence supporting the use of the 
Brief Pain Inventory-Short Form and Revised Short McGill Pain Questionnaire 
Version-2 in Musculoskeletal Conditions? 
2. What is the reproducibility (reliability and agreement parameters) and internal 
consistency of the Revised Short McGill Pain Questionnaire Version-2 for use among 
patients with musculoskeletal shoulder pain? 
Composition of Dissertation Papers 
This dissertation consists of two papers presented in a manuscript style as Chapters 
two and three. Chapter two is a systematic review manuscript. Chapter three is a research 





patients with shoulder pain. The systematic review (Chapter – 2) examined the quality and 
content of measurement evidence reported for the Brief Pain Inventory-Short Form and 
Revised Short McGill Pain Questionnaire Version-2 in pain-related musculoskeletal 
conditions. In this review, we synthesized, appraised and compared reported evidence on the 
measurement properties of both outcome tools. The critical appraisal involved two methods 
that checked the quality and risk of bias (the COSMIN guidelines) and the rigor of authors 
report of measurement properties (MacDermid’s tools). The review findings helped us 
identify the gaps in the literature which informed our objective in the third chapter of the 
dissertation.  
The third chapter of the thesis comprehensively examined the reliability and 
agreement properties of the Revised Short McGill Pain Questionnaire Version-2 among 
patients with musculoskeletal shoulder pain. In this study, the internal consistency, test-retest 
reliability, standard error of measurement (SEM), minimal detectable change (MDC) and 
Bland-Altman methods were used to assess the reproducibility of the SF-MPQ-2. The results 
of the study established evidence in support of the reproducibility of the SF-MPQ-2 for use 
among adults with shoulder pain. In summary, research in this thesis attempts to address the 
literature gaps in measurement evidence by systematically summarizing the available 
evidence on the psychometric properties of the Brief Pain Inventory-Short Form and Revised 
Short McGill Pain Questionnaire Version-2 and evaluating the reproducibility of Revised 
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Study design: Systematic review of clinical measurement studies. 
Background: The BPI-SF and SF-MPQ-2 are general-use, self-report, multidimensional pain 
measures frequently used in musculoskeletal (MSK) conditions. Synthesizing knowledge of 
their measurement properties, as assessed in MSK conditions, should provide a deeper 
understanding of their strengths and limitations. 
Objectives: To systematically locate, critically appraise, compare and summarize clinical 
measurement research addressing the use of BPI-SF and SF-MPQ-2 in pain-related 
musculoskeletal conditions.   
Methods: Four databases (Medline, CINAHL, EMBASE & SCOPUS) were systematically 
searched for relevant citations, each for the BPI-SF and SF-MPQ-2. We included articles 
reporting the psychometric properties (e.g. validity, reliability, responsiveness) and 
interpretability indices (e.g. minimal clinically important difference) of both tools, as assessed 
in mixed and specific MSK studies. Independently, two reviewers extracted data and assessed 
the quality of evidence with the MacDermid’s measurement studies quality assessment tool 
and the updated COnsensus-based Standards for the selection of health Measurement 
INstruments (COSMIN) guidelines. 
Results: Twenty-five articles were included (BPI-SF, n=17; SF-MPQ-2, n=8). Both tools lack 
reporting on their cross-cultural validities and measurement error indices (standard error of 
measurement, minimal detectable change). High quality studies suggest the tools are 
internally consistent (α = 0.83-0.96), and they associate modestly with similar outcome 
measures (r = 0.3-0.69). There is strong evidence suggesting the BPI-SF conforms to its two-
dimensional structure in MSK studies; the SF-MPQ-2 four-factor structure was not clearly 
established. Seven reports of high-to-moderate quality evidence were supportive of the BPI-





available for the SF-MPQ-2. Furthermore, the SF-MPQ-2 was more frequently associated 
with floor effects in MSK studies than the BPI-SF (SF-MPQ-2, 42% vs BPI-SF, 6%). 
Conclusion: Although the SF-MPQ-2 presents potential, and both tools display high-quality 
evidence in support of their internal consistency and criterion-convergent validities, high to 
moderate quality evidence suggests the BPI-SF subscales have a better responsiveness, retest 
reliability, known group validity and structural validity than the SF-MPQ-2. Therefore, the 
BPI-SF is currently better for pain assessment in MSK conditions. However, 
methodologically sound studies are still needed for both tools’ measurement properties 
including their cross-cultural validities, retest reliability, measurement error indices, minimal 
clinical important difference and clinical important difference. 
Keywords: Brief Pain Inventory; McGill Pain Questionnaire; Musculoskeletal Conditions; 



















Musculoskeletal (MSK) conditions are among the leading causes of years lived with 
disability.15,53 Pain originating from MSK conditions has a significant impact on patients’ 
general wellbeing and commonly results in frequent visits to the emergency or outpatient 
department of hospitals and clinics.3,22 Patient-reported outcome measures (PROMs) are the 
primary methods of assessing and monitoring the patients’ pain experience, and well validated 
PROMs help clinicians make informed care decisions.27,30,44 A large number of PROMs with 
multidimensional scales now exist for pain assessment in various conditions including MSK 
disorders. The Brief Pain Inventory-Short Form (BPI-SF)8 and the Revised Short McGill Pain 
Questionnaire Version-2 (SF-MPQ-2)10 are examples of generic PROMs that are increasingly 
being used for pain assessment in musculoskeletal conditions: experts are currently presenting 
these tools as core outcomes for pain assessment in chronic musculoskeletal pain studies 
(BPI-SF)9,23 and complex regional pain syndrome (SF-MPQ-2 neuropathic subscale).13 
The BPI-SF contains 11-items evaluating the severity and interference of pain with 
daily functioning. Four items quantify patients’ responses on the severity of pain at its ‘worst’, 
‘least’, ‘on average’ and ‘now.’ Each of the four descriptors are anchored to a common 
scaling structure that has zero as ‘no pain’ and 10 as ‘pain as bad as you can imagine’. To 
obtain a total pain-severity score, the mean of the 4 severity items is computed. The 
interference subscale of the BPI-SF captures the patients’ perception of how pain impacts 
seven constructs: ‘mood’, ‘enjoyment of life’, ‘relationship with others’, ‘sleep’, ‘general 
activity’, ‘walking ability’, and ‘work’. Each of the seven items are equidistantly bounded on 
a zero-to-10 numerical rating scale having zero as ‘does not interfere’ and 10 as ‘completely 
interferes’. To obtain a total pain interference score, the mean of four or more of the 
interference items must be computed.7 
The Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2)10 was created 





concurrently evaluates the severity and characteristics/qualities of pain originating from both 
neuropathic and nociceptive sources. The SF-MPQ-2 has 22-items evaluating pain across four 
dimensions as follows: 1) continuous pain (throbbing, cramping, gnawing, aching, heavy, and 
tender pain); 2) intermittent pain (shooting, stabbing, sharp pain, splitting pain, electric-shock, 
and piercing pain); 3) neuropathic pain (hot-burning, cold-freezing, pain caused by light 
touch, itching, tingling or pins and needles, and numbness pain), and  4) affective pain (tiring-
exhausting, sickening, fearful, and punishing-cruel). Each pain descriptor is scored on a zero 
(none)-to-10 (worst possible) numerical rating scale. The total pain score is the mean of the 
22-items, while the total subscale scores are the mean of each of their respective descriptor 
cluster.10 
Like some generic tools, the BPI-SF and SF-MPQ-2 were originally developed and 
tested for pain assessment in specific-disease populations. For instance, the BPI-SF was 
originally developed for cancer pain assessment8,20 while the SF-MPQ-2 was purposefully 
expanded to include the neuropathic pain elements, and initially validated in a diverse chronic 
pain population with patients having conditions including neck and shoulder pain, and painful 
diabetic neuropathy.10 Currently, however, both tools are deemed useful for pain assessment 
in other conditions, including musculoskeletal conditions. Although evidence supporting the 
measurement properties of both tools has continued to accumulate, there has been no 
systematic inquiry on their performance as ‘general-use’ pain assessment tools in 
musculoskeletal conditions. Previous reviews of the BPI-SF5,6,43 and the SF MPQ-243 only 
summarized their measurement properties as examined in  back pain, with no report on other 
MSK conditions. 
However, by systematically extracting evidence from the pool of studies that have 
reported the BPI-SF and SF-MPQ-2 measurement properties in mixed and specific MSK 
populations, we expect to have a broader understanding of their measurement performance in 





and helps in selecting the appropriate outcome measure for use, for example, in 
epidemiological pain studies where these tools are sometimes employed.11 Furthermore, the 
methodological quality of a study places value on its report of measurement properties: 
therefore, a thorough critical appraisal of the measurement reports would help identify their 
risk of bias, which often modifies the strength accorded the studies’ conclusions.36 
Investigating the two questionnaires measurement properties is timely and will yield 
insights on how they efficiently assess pain in MSK conditions. Such knowledge can guide 
the preferences of the busy clinician/researcher encountering such conditions thus fostering 
evidence-based practice in MSK pain management. The objective of this review was to 
systematically locate, summarize, critically appraise, and compare the quality of measurement 
research utilizing the Brief Pain Inventory-Short form (BPI-SF) and the Revised Short McGill 
Pain Questionnaire Version-2 (SF-MPQ-2) in pain-related musculoskeletal conditions. 
METHODS 
Design 
This review followed the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement and checklist,35 and the protocol manuscript16 was registered 
with Prospero (CRD42018095862). The review was conducted in four steps: (a) 
comprehensive searches were performed in four bibliographic databases to identify relevant 
citations, each for the BPI-SF and SF-MPQ-2; (b) title, abstract and full-text were screened to 
fit pre-determined standards; (c) data on measurement properties were extracted; (d) in two 
phases, the MacDermid’s measurement studies quality assessment tool and the COSMIN 







Data Source and Search Strategy 
Search strategies developed in consultation with a health-research librarian were run 
last on the 10th of July 2019 in the Medline—OVID, EMBASE—OVID, CINAHL 
(Cumulative Index to Nursing and Allied Health Literature), and Scopus bibliographic 
databases to identify relevant citations. The search concepts for measurement properties were 
refined from a previous comprehensive search filter validated by Terwee et al50 and included 
different measurement property keywords (see Appendix 1). The search for studies 
addressing the BPI-SF properties was not restricted by time or language. However, the search 
for the SF-MPQ-2 articles was restricted by time to its year of first publication (i.e. January 
1st, 2009)10  in order to limit citations related to its parent versions (SF-MPQ and MPQ) but 
language was not restricted. 
Eligibility requirements  
Inclusion Criteria: 
(i) We included only studies whose purpose was to evaluate at least one of the measurement 
properties of the BPI-SF and SF-MPQ-2 in a sample population characterized with MSK 
conditions fully, or to an extent that satisfies 70-percent of the study sample size. 
(ii) We included studies with available full text, published in a peer-reviewed journal in any 
language and conducted in a population within the age of 16 years and above. 
Exclusion Criteria: 
(i) We excluded all letters to the editor, review articles, book reviews and short 
communications, clinical protocols, case reports, animal studies, and series. 
(ii) We excluded studies without explicit evidence that describe pain to be of MSK origins 





used to define the sample populations’ pain, such as, ‘non-malignant pain’ or ‘chronic pain’ or 
‘non-cancer pain’ without clearly relating such pain to be of MSK origin fully, or partly.   
(iii) We excluded studies conducted in disability or pain-related conditions that were primarily 
due to some of the following: congenital and developmental abnormalities, neoplasm, 
infection, surgical procedures not due to MSK conditions (e.g. coronary heart surgery, 
laparotomy), neurological or neuropathic pain (undefined as lumbar, cervical or thoracic 
radiculopathies with back pain), or HIV/AIDS pain. 
Study selection and screening  
Prior to the screening/selection phases, articles retrieved from each database were 
exported to the Covidence systematic review software (Veritas Health Innovation, Melbourne, 
Australia - available at www.covidence.org), for de-duplication and study selection. In line 
with the eligibility requirements, the screening/selection took place in two steps: first, title and 
abstracts were independently screened for obviously unrelated articles. We then assessed the 
full text of emerging articles for congruency with the aims and eligibility requirements of the 
review. A further hand search of the included studies reference list was conducted, each for 
the BPI-SF and SF-MPQ-2, to identify any other relevant citations. All disagreement during 
the selection were discussed and settled among the screening authors (JS and MK). 
Data extraction 
We extracted data from individual studies using a structured data extraction form 
developed from the guide available in the second author’s (JCM) work.28 Two review authors 
(JS and MK) worked independently to extract data from the included studies, and a third 
review author was to be contacted if any disagreement arose. When reported, the following 
information were extracted: floor-ceiling effect, construct validity (criterion-convergent and 





factor analysis]), reliability (test-retest), responsiveness (AUC’s, change correlation indices, 
standardized response mean [SRM], effect-size [ES]), interpretability properties (clinically 
important difference [CID], minimal clinically important difference [MCID]), measurement 
error indices, and measurement invariance/cross-cultural validities. Data was summarized 
according to the subscale of the tools evaluated. To guide our review, painful MSK conditions 
were defined as disorders affecting the muscles, bones, soft tissue, joints and spine.40 We then 
classified the acceptable studies into populations as follows: 
a) ‘Mixed’ MSK population studies: studies that satisfied the requirements of ≥ 70-percent 
sample size proportion representing MSK conditions of different mechanism or 
pathophysiology or described by different body regions. 
b) ‘Specific’ MSK population studies: those conducted among homogenous MSK samples 
described by the body region affected or the pathophysiology/mechanism.  
We also extracted information on: (a) the characteristics of the studies, for example, 
country where the study was conducted, language, study design, study setting, the SF-MPQ-2 
and BPI-SF language/version/subscale/item used, and (b) participants characteristics including 
sample size, age, and sex. 
Review Team Hypotheses 
The following hypotheses, as suggested by the COSMIN36,38 initiative, were defined in 
advance by the review team to guide the quality assessment phase. 
a) Correlations between the two questionnaires and other pain/health-related outcome tools 
were expected to be 0.3 and above in magnitude. Correlations were then classified as low to 
moderate at 0.3-0.69; high at 0.7 and above.28,32   
b) The lower bound confidence intervals of reports supporting Area Under the Curve (AUC) 





c) We described the correlation indices between the change scores of other pain/health-related 
outcome measures and the two questionnaires as sufficient at ≥ 0.3.  
However, the review team could not define hypotheses to assess authors 
responsiveness report based on the standardized response mean (SRM) and effect size (ES) 
indices. As such, article authors were expected to provide context-specific hypotheses that 
defined the magnitude and direction of expected change.  
Quality Assessment 
Quality assessment was conducted in two phases: first, the MacDermid’s measurement 
studies quality assessment tool26 was used to appraise the included studies. Next, the 
COSMIN guidelines36,41,42,49 were used to examine methodological risk of bias and to 
compare reported measurement properties against benchmark quality standards. Both phases 
of quality assessment were deemed complementary. 
Phase 1: Quality, Comprehensiveness and Breadth of Measurement Evidence Reports 
  An initial calibration meeting informed the reviewers’ (JS and MK) independent 
appraisal of the included articles. MacDermid’s measurement studies quality assessment tool26 
was used to examine the quality, breadth and rigor of authors report against 12 criteria. Where 
applicable, each criterion receives: 0-points, if judged, ‘not done/documented’ OR ‘substantial 
inadequate’ OR ‘inappropriate’; 1-point, if judged, ‘acceptable but suboptimal’; and 2-points, 
if judged, ‘consistent with best practice’, and NA if judged ‘Not Applicable’ to a study. An 
article can receive a total score ranging from zero (lowest) to 24 (highest) points, which can 
be converted to a percentage that represents its total quality rating. Percentile scores were 
interpreted as follows: poor quality report, 0%–30%; Fair, 31%–50%; Good, 51%–70%; Very 







Phase 2: Risk of Bias Assessment and Quality of Measurement Properties 
In this phase, the same review authors (JS and MK) independently assessed the 
included studies for conformity with the COSMIN risk of bias (RoB)38,41 and quality criteria 
checklists.42,49 The RoB checklist consists of 10 boxes, each representing a measurement 
property featured in the COSMIN consensus-based taxonomy.37 Irrespective of the 
terminology used to define measurement properties by individual authors, we defined all 
measurement properties according to the COSMIN consensus-based taxonomy of 
measurement properties,37 and that determined the corresponding box to complete for the risk 
of bias assessment. Each of the risk of bias assessment box contains several items/questions 
that are scored on a 4-point rating scale as ‘very good’, ‘adequate’, ‘doubtful’ and 
‘inadequate’.38 The lowest rating for any item/question on a study’s measurement property 
determines its overall rating for methodological risk of bias based on the worst score count 
system. Of the ten boxes in the COSMIN risk of bias checklist, we ignored two boxes: PROM 
development and content validity, because the BPI-SF and SF-MPQ-2 were not initially 
validated in study populations satisfying our inclusion criteria.36,38 
In the second phase of the COSMIN quality assessment, all the extracted data on 
measurement properties for each of the tools were rated against the good measurement 
property quality criteria, as available in the COSMIN User’s Manual Version-1.36,42,49 Based 
on the category of the measurement property reported (e.g. internal consistency, test-retest 
reliability), studies were compared and rated against the COSMIN quality criteria as: 
‘Sufficient’ (+), if within the benchmark quality criteria; ‘Indeterminate’ (?), if there was an 
inadequate report to compare to the benchmark quality criteria, and; ‘Insufficient’ (-), if the 







To determine the level of evidence supporting the two questionnaires measurement 
properties, we applied the Modified GRADE  (Grades of Recommendation, Assessment, 
Development, and Evaluation) as described by the COSMIN initiative.36 In our synthesis, 
more attention was given to the consistency of reports contained in studies with ‘sufficient’ 
(+) quality ratings (which is the acceptable quality criteria rating) and prone to lesser risk of 
bias: that is, with ‘very good’ or ‘adequate’ risk of bias rating. First, we pooled/summarized 
the results extracted on each measurement property, per tool. For example, the estimated 
intraclass correlation coefficient (ICC) for the BPI-SF and SF-MPQ-2 was summarized using 
a weighted average. Cronbach alpha for internal consistency was summarized using the 
observed range of occurrences across the studies with a low risk of bias. Proportions were 
used to summarize the number of correlations within the low-to-moderate range (rho = 0.3-
0.69), and ‘high’ range (rho ≥ 0.7). For structural validity, responsiveness and known group 
validity, we considered the number of studies with a low risk of bias rating available on each 
of those measurement properties, per tool, and used narrative synthesis to summarize their 
findings. Conclusions were formulated using the Modified GRADE level of evidence 
approach while considering the risk of bias, inconsistency, imprecision and indirectness of the 
pooled results, under the assumption that all the captured conditions were MSK conditions, 
regardless of their type (mixed or specific).38,41 The same pair of reviewer (JS and MK) 
conducted both phases of the quality assessments and synthesis, independently, in line with 
the review teams hypotheses. The review authors met and discussed their ratings until 








Figure 1 summarizes the review screening and selection processes. Our searches 
identified 1267 unique citations after de-duplication. We reviewed 92 articles in full text after 
the title and abstract screening phase. In total, 25 articles satisfied the review teams 
criteria.1,4,11,12,14,17–22,24,25,29,31,33,39,45–48,51,52,54,55 Seventeen (17) articles assessed the BPI-SF in 
16 studies, while 8-articles evaluated the SF-MPQ-2 in 7-studies. Each of the tools had two 
articles (BPI-SF21,22 and SF-MPQ-211,51) that reported from one study population and their 
results were merged in this review. Some studies only focused on a particular subscale of the 
BPI-SF,12,31,55 or did not assess the BPI-SF as a primary outcome,14,19,21,45 whereas all the SF-
MPQ-2 subscales were always examined as primary outcomes aside one that assessed only the 
neuropathic subscale.39 
The characteristics of the MSK populations assessed in the included studies are 
summarized in Table 1. Eight studies evaluated different measurement properties of the BPI-
SF4,12,19,21,22,24,47,48 in Mixed-MSK population studies; three examined the SF-MPQ-2.1,25,29 
One or more measurement properties of the BPI-SF were assessed in Specific-MSK 
population studies with conditions including fibromyalgia,31 back pain,20,46,54 knee pain,45 hip 
pain,18 osteoporosis,14 and arthritis20,33,55 while subscales of SF-MPQ-2 were examined among 
knee pain,29,52 complex regional pain syndrome (CRPS),39 and acute back pain11,51 patients. 
Although a wide range of measurement properties were assessed for both tools, studies 
reporting measurement error indices (MDC and SEM), cross-cultural validities, and 
interpretability properties (CID and MCID) were scarce. 
Quality of the Included Studies  
All the included studies were first inspected with MacDermid’s quality assessment 
tool and Table 2 summarizes the total quality score of each article. The BPI-SF articles 
received quality ratings within 50% to 86%, with a mean of 67% whereas the SF-MPQ-2 





rating in favor of the SF-MPQ-2 was not surprising because it was consistently assessed as a 
primary outcome in the included studies. The BPI-SF, however, was often utilized as a 
comparator or secondary outcome in 4 (23%) of the included studies14,19,45,54  which impacted 
negatively on its mean quality rating for some criteria assessed with the MacDermid’s quality 
assessment tool.  
However, some quality issues were common to both tools: a) the absence of sample-
size calculation or rationalization, b) imprecise or unclear hypotheses, c) limited or 
insufficient description of test procedures to an extent that allows replication of methods, d) 
absence or minimal reporting of error estimates (confidence intervals, SEM), and e); over-
exaggerated or out-of-context conclusions/recommendations (see Table 2). Raters’ agreement 
was excellent, as indicated by a high inter-rater reliability for the summary of their quality 
rating scores (ICC 0.87; 95% CI,  0.79–0.92) and unweighted kappa for individual item scores 
(0.75). All disagreements between the raters at this phase were clarified by the second author 
(JCM). 
The results of the second phase of the quality assessment according to the COSMIN 
guidelines are summarized in the subsequent headings below, alongside evidence on the 
extracted measurement properties. Tables 3 to 5 contain details on the BPI-SF measurement 
properties, the MSK population they represent, and their quality rating as assessed, first, with 
the COSMIN risk of bias (RoB), then, as benchmarked against the COSMIN quality criteria. 
Table 6 summarizes the same details for the SF-MPQ-2. Finally, Table 7 summarizes the 
result of the level of evidence synthesis for both tools, as per the modified GRADE. 
Floor /Ceiling Effects, MCID and CID 
Floor/ceiling effects occurs when a significant number of responders select scores that 
concentrate at the lowest (floor) and on the highest (ceiling) limits of a PROM.49 When 





floor effects in studies assessing MSK conditions. Only Kapstad and colleaques18 found 
significant flooring on the BPI-SF severity [21%] and interference [28%] subscales among 
total hip replacement patients 1 year post-op (Table 4). In contrast, three studies1,11,25 reported 
flooring on the SF-MPQ-2 subscales: Lovejoy et al.25 found significant flooring in a ‘mixed’ 
study population on the affective (28%), intermittent (15.1%) and neuropathic (12.4%) 
subscales of SF-MPQ-2; Adelmanesh et al1 reported less significant floor effects (3.5-8.7%) 
while Dworkin et al.11 noted some floor effects on the affective subscale (15%) among 
patients with acute back pain (Table 6). 
Only one well-powered study (n= 1411)31 reported MCID and CID within 2.09-2.89 
for the BPI-SF severity and average pain item among fibromyalgia patients (Table 4). No 
study has investigated the MCID or CID of the SF-MPQ-2. 
Test-retest reliability 
Few studies have examined the retest reliability of the BPI-SF and SF-MPQ-2 in MSK 
conditions. Three studies assessed the BPI-SF, but pooled evidence from two studies4,55 
displayed a high level of evidence supporting the interference subscale retest-reliability; the 
weighted ICC was ‘sufficient’ at 0.83. One report4 of ‘adequate’ RoB rating was available in 
support of BPI-SF severity subscale retest reliability (ICC, 0.83) but further assessment with 
the modified GRADE suggest it represents a low level of evidence due to its low sample size 
(n=71) and RoB rating (Table 3). One study was rated ‘doubtful’ on the BPI-SF because the 
stability of patients was not certain.33 Four studies examined the SF-MPQ-2 retest reliability: 
only one17 received an ‘adequate’ RoB ratings, with ICC scores within 0.73-0.90 but 
represented a low level of evidence on the COSMIN Modified GRADE due to its small 
sample size (Table 6 & 7). The remaining three studies1,29,52 were rated ‘doubtful’ because of 





were long enough for change to occur (3 months)52 or short enough (7-hours) to allow recall 
bias1 were reported (Table 6).  
In conclusion, although not consistent across all its subscales, the COSMIN modified 
GRADE suggests a ‘moderate’ level of evidence of ‘sufficient’ quality currently supports the 
BPI-SF retest reliability which is relatively stronger than the evidence for the SF-MPQ-2, with 
‘very low’ level of evidence of ‘insufficient’ quality. 
Internal consistency 
Internal consistency was the most frequently reported form of reliability among the 
reviewed articles, and a high level of evidence supports both tools internal consistency in 
MSK studies. For the BPI-SF, eight studies with low RoB ratings (7 = ‘very good’; 1 = 
‘adequate’)4,12,18,20,33,48,55 reported Cronbach alpha within 0.82 - 0.96 (Table 3). Of the five 
studies that examined the SF-MPQ-2, four11,17,25,29 had ‘very good’ ratings for RoB, with 
Cronbach alpha within 0.88-0.96 (total score), and 0.75-0.92 (subscales scores). The only 
inadequate study failed to confirm the dimensionality of a translated version of the SF-MPQ-2 
before reporting Cronbach alpha for the total scale score1 (Table 6). In summary, the 
COSMIN Modified GRADE suggest a ‘high’ level of evidence of ‘sufficient’ quality supports 
both tools internal consistency in MSK conditions. 
Structural Validity (hypothesis testing) 
Studies have addressed questions on the multidimensional structure of the BPI-SF and 
SF-MPQ-2 in various MSK conditions. Seven reports with ‘very good’ RoB ratings examined 
the structural validity of the BPI-SF using factor analysis: four studies4,20,33,48 were classified 
as ‘indeterminate’ because authors did not report details comparable to the COSMIN quality 
criteria; the remaining three studies12,24,46 were ‘sufficient’ and displayed a high level of 





factor solution explaining the BPI-SF severity and interference subscales was more optimal 
than a three or one factor solution among mixed24 and low back pain46 patients, respectively. 
Also, Farrere et al.12 confirmed the Portuguese interference subscale conformed with a one-
factor solution, as originally hypothesized for the English version (Table 4). 
Four studies examined the SF-MPQ-2 using factor analysis; however, pooled evidence 
from two high quality studies (‘very good’ RoB rating) displayed a conflicting quality of 
evidence in support of the SF-MPQ-2 factor structure in MSK condition. Although Dworkin 
et al.11 proposed a four-factor solution for the SF-MPQ-2, all but the ‘neuropathic subscale’ 
did not confirm their proposed hypothesis. The study received a ‘very good’ risk of bias rating 
but was ‘insufficient’ when compared against the COSMIN quality criteria. Conversely, 
Lovejoy and co.25 showed that factor analysis indices (root mean square error of 
approximation [RMSEA], Tucker-Lewis index [TLI], comparative fit index [CFI], Akaike 
information criterion [AIC]) favoured a four-factor solution over a one-factor solution (Table 
6); the study was ‘very good’ on RoB assessment and ‘sufficient’ against the COSMIN 
quality criteria. Two studies were not included in the evidence synthesis: the first was 
‘inadequate’ on RoB assessment because it was underpowered (less than 100 participants)29 
while the other study1 was ‘indeterminate’ from the lack of comparable details with the 
COSMIN criteria.  
Turner and colleagues52 used a ‘very good’ methodology in their Rasch analysis of the 
SF-MPQ-2 structure. Their findings suggest the SF-MPQ-2 is structurally unstable for use 
among patients with knee pain: the total scale score exhibited some form of dimensionality 
and differential item functioning. Furthermore, although the continuous, intermittent and 
affective subscales were unidimensional, some item misfit (1, 8 and 9) and disordered 
response thresholds were noted (Table 6). Packham et al.39 also examined the SF-MPQ-2 
neuropathic subscale structural stability using Rasch analysis among complex regional pain 





item difficulty was adequate. Although the study received a ‘very good’ RoB rating, it was 
underpowered (n= 57) and thus, of ‘insufficient’ quality according to COSMIN standards. 
Overall, synthesis based on the COSMIN Modified GRADE suggest a ‘high’ level of 
evidence of ‘sufficient’ quality supports the structural validity of the BPI-SF; hence, it 
comparatively better than the SF-MPQ-2 with ‘high’ level of evidence but of ‘conflicting’ 
quality (Table 7). 
Known-groups validity 
Authors have tested a spectrum of hypotheses to confirm the ability of the two 
outcome measures to differentiate known groups, but very few reports came from studies with 
good methodological approaches. Of the ten hypotheses tested with the BPI-SF, only four 
reports received ‘very good’ RoB ratings: Stubbs et al47 demonstrated the ability of the BPI-
SF to discriminate elderly patients with mixed MSK conditions into known groups of 
recurrent fallers and non-fallers, beyond chance (AUC, 0.72-0.73); however, two more 
hypotheses posited in the same study about the BPI-SF ability to differentiate fallers from 
none-fallers failed (AUC < 0.7).47 Six additional hypotheses20,46,55 examined the 
discriminative ability of the BPI-SF to categorize back pain and osteoarthritis patients into 
different groups of varying pain severities (Mild, Moderate, Severe, etc.). The findings were 
rated ‘inadequate’ on RoB assessment and ‘indeterminate’ against the COSMIN quality 
criteria from the use of poor statistical approaches and unclear definitions of known groups 
(Table 4 ), which was not different from our findings among the studies that reported on the 
SF-MPQ-2 known group validity11,25 (Table 6).  
To conclude, the COSMIN Modified GRADE indicates a ‘moderate’ level of evidence 
of ‘sufficient’ quality supports the BPI-SF known group validity in MSK studies while a ‘very 
low’ level of evidence of an ‘indeterminant’ quality supports the SF-MPQ-2 known group 






Criterion-convergent validity was the most investigated psychometric property on the 
two questionnaires. A sizable number of health-related outcome measures (n=22) correlated 
with the BPI-SF and SF-MPQ-2 in different MSK populations, and all but 2 studies received 
‘very good’ and ‘sufficient’ ratings on RoB assessment and against the COSMIN quality 
criteria. Furthermore, established correlations were mostly low-to-moderate in magnitude 
(BPI-SF, 78%; SF-MPQ-2, 67%) (Table 4 & 6).  
When disease/region specific PROMs like the Western Ontario and McMaster 
Universities Arthritis Index, Oswestry Disability Index, Roland Morris Disability 
Questionnaire were associated with subscales of the BPI-SF18,20,22,33,46,48,55 and SF-MPQ-2, 17 
relationships were predominantly low-to-moderate (r = 0.3-0.69). Similarly, low-to-moderate 
(r = 0.3-0.67) correlations were observed with mental/psychological status questionnaires: for 
instance, the SF-MPQ-2 correlated with the Beck Depression Inventory (BDI-II), the 
Generalized Anxiety Disorder-7 scale (GAD-7) and the Hospital Anxiety and Depression 
Scale,11,25 while the BPI-SF subscales demonstrated  an association with the Hospital Anxiety 
and Depression Scale.12,20  
When generic PROMs were associated with the two questionnaires, correlations were 
mostly low-to-moderate (0.3-0.69) (Table 4 & 6); however, a few high associations (r ≥ 0.7) 
were seen in Mixed-MSK studies between subscales of the BPI-SF and the Short Form Health 
Questionnaire (SF 36)20 and the Chronic Pain Grade scale.20,22  Similarly, the SF-MPQ-2 
correlated highly (r ≥ 0.7) with the pain Numeric Rating Scale and the Pain Disability Index 
among complex regional pain syndrome patients;39 the Visual Analogy Scale1 and the 
Multidimensional Pain Index25 in a mixed-MSK population, and with the SF-MPQ-2 parent 
versions (MPQ and SF-MPQ) among patients with knee pain.29 In summary, a ‘high’ level of 
evidence of ‘sufficient’ quality supports both tools criterion-convergent validities in MSK 





(r = 0.3-0.69) although a few higher correlations were seen with generic tools in mixed 
studies.  
Responsiveness 
The responsiveness of the BPI-SF was more extensively investigated than the SF-
MPQ-2 in MSK conditions. Eighteen reports14,18–21,45,48,54 were available on the BPI-SF 
responsiveness, but only five14,19,21,54 received ‘very good’ RoB and ‘sufficient’ quality 
ratings. Two good quality studies, based on the construct approach, reported low-to-moderate 
correlations (0.30-0.69) between change scores of the BPI-SF, and the generic EQ-5D54 (low 
back pain) and disease-specific Osteoporosis Quality of Life Questionnaire14 (osteoporosis 
patients). The receiver operator curve (ROC) approach was adopted in the remaining three 
‘good’ quality studies: in one report, the BPI-SF subscale was able to discriminate improved 
low back pain patients beyond chance (AUC ≥ 0.7)54; the other two reports in Mixed-MSK 
populations supported the ability of the  BPI-SF to discriminate patients that experienced ‘any 
improvement’ from those with ‘moderate improvement’.19,21 However, the interference 
subscale did not satisfy the review teams criteria (AUC > 0.7).19  
Nine reports18–21,45,54 based on the effect size (ES) and standardized response mean 
(SRM) approach to responsiveness, were rated ‘adequate’ on RoB assessment but 
‘indeterminate’ against the quality criteria. All nine reports lacked clearly stated hypotheses 
that defined the magnitude and direction of expected change: for instance, it was impossible to 
tell if the reported ES or SRM supported the effectiveness of administered interventions, or 
the responsiveness of the outcome measure to capture change as expected.36 Four reports from 
three studies20,48,55 were also rated ‘inadequate’ and ‘insufficient’ from their poor design or 
use of suboptimal statistical approaches, such as Guyatt statistic, co-variances, t-test statistic 





Four studies1,11,25,39 addressed the SF-MPQ-2 responsiveness in MSK conditions: one39 
among CRPS patients was ‘adequate’ on RoB assessment but ‘indeterminant’ against the 
COSMIN quality standards because the authors did not define the expected change directions 
or magnitude. The remaining three studies were ‘inadequate’ and ‘indeterminant’ because 
authors employed suboptimal statistical approaches (Table 6). In summary, evidence 
synthesis according to the COSMIN Modified GRADE suggest the BPI-SF has a ‘high’ level 
of evidence of ‘sufficient’ quality in support of its responsiveness from 5 studies. On the 
contrary, a ‘very low’ level of evidence of ‘indeterminant’ quality was seen across seven 
studies for the responsiveness of the SF-MPQ-2. 
DISCUSSION 
Our systematic review indicates that better quality of evidence currently supports the 
psychometric properties of the BPI-SF over the SF-MPQ-2. Although not a head-to-head 
comparison, evidence synthesis based on COSMIN guidelines36–38,41,42,49 suggest both tools 
have high-quality evidence supporting their internal consistency and criterion-convergent 
validities. However, sufficient evidence of high-to-moderate quality only supports the BPI-SF 
responsiveness, retest reliability, known group validity and structural validities as compared to 
the SF-MPQ-2 in MSK conditions (Table 7). In addition, more articles described floor effects 
on the SF-MPQ-2 than was reported with the use of the BPI-SF. 
Two different, but complementary approaches to appraising the quality of 
measurement evidence of outcome tools were employed in this review. Although quality 
ratings favoured the SF-MPQ-2 over the BPI-SF when the structured clinical quality 
assessment tool was used, quality assessed according to the COSMIN guidelines favoured the 
BPI-SF. The SF-MPQ-2 only received higher quality rating in the initial phase of assessment 
because it was often the primary focus of psychometric investigations, not because the reports 





number assessed measurement properties with sound methodological approaches which 
favoured the BPI-SF quality ratings when assessed with the COSMIN guidelines. This finding 
suggest that the quality or comprehensiveness of a study report does not rule out the 
tendencies of bias in the evidence; however, insufficient reporting can expose otherwise good 
evidence to bias. 
 Many of the included studies (42%) reported remarkable floor effects on select 
subscales of the SF-MPQ-2. This may relate to the quality/characteristic of pain captured on 
the 22-item descriptors of the SF-MPQ-2.10 Not all characteristics of pain may be similarly 
represented in MSK conditions and the variation in patient scores on the SF-MPQ-2 subscales 
may selectively reflect unique pain phenotypes within MSK conditions. This ultimately 
predisposes some of the subscales of the SF-MPQ-2 to floor effect. For instance, high mean 
scores on the neuropathic pain subscale is unlikely if participants perceive pain as nociceptive. 
Similarly, it is unlikely for very resilient participants to report high scores on the SF-MPQ-2 
affective subscale. Therefore, the floor effect on subscales of the SF-MPQ-2 does not 
necessarily represent redundancy but reflect its discriminative nature. Future studies may 
explore this speculation. 
The available high-quality evidence on internal consistency and structural validity 
supports the stability of the BPI-SF. Cronbach alpha was satisfactory and the original 2-factor 
structure (severity and interference), as hypothesized during the BPI-SF development, was 
reproduced.7,8 However, it was notable that several studies4,20,33,48 had an indeterminate 
quality assessment rating because authors failed to report comparable indices even though 
they mostly suppose the BPI-SF conforms with a 2-factor solution (Table 4). There is yet to 
be a Rasch analysis on the BPI-SF structural validity in a well-represented MSK population; 
the single Rasch paper identified during screening53 failed to satisfy our inclusion criteria  ≥ 
70% threshold for MSK participants. Therefore, future authors should review the COSMIN 





SF, and a Rasch analysis should be performed in a population that sufficiently represents a 
spectrum of musculoskeletal conditions. 
For the SF-MPQ-2, internal consistency was established, but a conflicting (+/-) quality 
of evidence displayed with its use in different MSK conditions. This happens periodically 
with multidimensional tools and may suggest that the questionnaire’s factor structure varies 
with the context of use.2  Mixed results of the item response examination of the SF-MPQ-2 
using Rasch methods has been documented. Packham and colleagues36 utilized ‘very good’ 
methods to examine the SF-MPQ-2 neuropathic subscale with the Rasch. Although their 
evidence supported the independent use of the neuropathic scale for CRPS assessment, the 
study was rated insufficient according to the COSMIN quality criteria because of its small 
sample size (n=57). In contrast, Turner and colleagues52 showed that the SF-MPQ-2 structure 
did not fit with the Rasch as assessed among a representative sample of knee pain subjects. 
Overall, it is too early to draw conclusions from the conflicting evidence on the SF-MPQ-2 
structural validity in MSK conditions until more high-quality evidence emerges from studies 
conducted in different MSK populations. Pooled evidence from such studies could be 
synthesized to provide conclusive evidence in future reviews on the SF-MPQ-2.  
Evidence for convergent-criterion related validities have been reported for both 
assessment tools in studies of high quality. It was noteworthy that the reported correlation 
with disease-specific/regional tools were consistently low-to-moderate (rho = 0.3-0.69) in 
most of the included studies. This could be from differences in concepts used to describe pain 
in generic and specific tools. While generic tools are structured to capture pain in multiple 
conditions, specific/regional tools are designed to elicit responses on patients’ pain in 
homogenous conditions. Although not entirely clear, these differences could underpin why 
correlations were only low-to-moderate when the tools were used in homogenous conditions. 
Test-retest reliability was among the least examined measurement properties across 





the interference subscale of the BPI-SF has been shown to have satisfactory intraclass 
correlation coefficient in support of its test-retest reliability and has received a high-quality 
rating for use in MSK conditions. Both the BPI-SF severity subscale and the SF-MPQ-2 
questionnaire lack high quality studies on their retest reliability. Some recurring flaws 
identified during the risk of bias assessment included: a) non-specification of the ICC model 
used in study analysis, preferably the two-way random effect model,36 b) low sample sizes, c) 
employment of suboptimal retest-intervals, and d) the unverified assumption of participant 
stability. Therefore, well-powered  high-quality studies that measure the test-retest reliability 
of the BPI-SF severity subscale and the SF-MPQ-2 are needed. Again, authors should 
consider adhering to the COSMIN reporting guidelines, and vague descriptions of patient 
stability should be avoided; if necessary, a Global Rating of Change score can be used to 
confirm stability in doubtful situations. Finally, robust estimates on the measurement error 
indices (SEM and MDC) of both tools should be pursued in different MSK populations.  
One of the most important findings from this review relates to evidence backing the 
two questionnaires responsiveness and known group validity in MSK conditions. Although 
high quality evidence supports the BPI-SF responsiveness in MSK conditions,14,19,21,54 studies 
that assessed responsiveness using the standardized response mean (SRM) and effect size 
(ES) were ‘indeterminant’ because authors did not provide well-defined hypotheses with clear 
magnitude and direction of expected change.36,38 The expected effectiveness or ineffectiveness 
of interventions differ and hypotheses testing responsiveness have to be precise and based on 
the context. For instance, smaller outcome measure change score indices are predicted in a 
study of a specific low intensity intervention than a high intensity intervention in the same 
population. Although the reported change scores would differ, both would generate support 
for the ability of the measure to detect change if the change scores were proportional to the 
intervention intensity. It is possible that authors ignored the importance of documenting this 





computations of ES and SRM responsiveness indices came from RCTs which had a secondary 
aim of examining outcome measurement performance.19,21,54,55 For known group validity, we 
only observed a moderate level of evidence in support of the BPI-SF since the available 
evidence of sufficient quality focused on older adults (indirectness). Future studies examining 
the responsiveness of BPI-SF, based on the ES and SRM approach need to provide precise 
hypotheses that specify the magnitude and direction of expected change. Furthermore, high 
quality studies are still needed in diverse age groups to explore known group validity of the 
BPI-SF. Unfortunately, we are unsure of the evidence on the known group validity and 
responsiveness of the SF-MPQ-2 in MSK population because studies of ‘very low’ and 
indeterminant quality rating were found for both properties in MSK conditions. This gap 
should be addressed in high-quality studies, bearing in mind that the SF-MPQ-2 was primarily 
developed/expanded to be able to discriminate patients by the quality of pain they 
experience,10 and it is highly important that clinicians/researchers are sure that a pain 
assessment tool is able to detect a change in the patient’s condition.2,28,32 
Valid and accurate MCID and CID estimates are important for outcomes evaluation, 
prognostication and communication among health care professionals.28,32,44 Unfortunately, 
only one well-powered study has reported the MCID and CID indices of the BPI-SF severity 
subscale and the average pain item among fibromyalgia using the anchor-based approach.45 
This lone report, however, is inadequate to permit informed decision-making considering the 
diversity of MSK conditions with multiple conditions requiring estimates on their MCID and 
CID, and the lack of estimate for the interference subscale. Even worst, no study has assessed 
the SF-MPQ-2 MCID and CID in any MSK population. Multiple studies aimed at estimating 
the MCID and CID of the two questionnaires are urgently recommended since these estimates 






In the present review, different ‘mixed’ and ‘specific’ MSK conditions were 
investigated with the two questionnaires but it was obvious that none of the studies 
exclusively reported the measurement properties of the tools in upper extremity conditions 
(e.g. carpal tunnel syndrome, tennis elbow, shoulder pain/dysfunction) and neck-related MSK 
conditions. Nonetheless, categories of MSK conditions such as neck and shoulder pain are 
common and frequently present to clinicians. Future studies should consider investigating the 
two questionnaires measurement properties in these classes of MSK conditions. Moreover, it 
will be of great benefit to the clinician managing mixed or peculiar upper extremity and neck 
MSK pathologies to be able to use outcome measures that not only assess the 
multidimensional nature of pain, but at the same time yield scores comparable across different 
studies. 
LIMITATIONS 
Our study has some limitations. First, our inclusion criteria considered only studies 
reporting measurement properties from sample populations with ≥70% MSK sufferers. 
Therefore, relevant reports of individuals with MSK disorders may have been overlooked or 
omitted because the reports did not meet our defined inclusion criteria. Second, we were 
unable to conduct a meta-analysis on the reported measurement properties across the included 
studies. This was due to gross differences in study methodology, MSK population 
characteristics, and the time intervals adopted in individual studies. However, our summary 
tables and narrative synthesis should be comprehensive enough to allow the 
clinician/researcher to understand the measurement properties accompanying the tools in 
peculiar MSK conditions, while at the same time, having an idea of their general performance 
in MSK conditions.  
Third, in comparing the measurement properties of the two questionnaires, based on 





culturally adapted/translated versions. While clinometric experts discourage this, it may not be 
problematic in this review because the evidence backing the culturally adapted/translated 
versions were mostly similar to the original versions. For example, culturally 
adapted/translated versions and original versions exhibited similar factor structures, their 
internal consistency estimates were within a similar range, and when cross-cultural 
adaptations were performed, authors confirmed compliance with standardized procedures to 
ensure content reflected the same concepts with the tools’ original versions. Nonetheless, 
specific details on the adapted/translated versions measurement properties and their quality 
ratings are available for consideration in our result Tables 3 to 6. 
CONCLUSION 
Although the SF-MPQ-2 presents potential, a greater volume of better-quality 
evidence was found in support of the BPI-SF measurement properties, including its 
responsiveness, retest reliability, known group validity and structural validities, which suggest 
it is currently better for pain assessment in MSK condition. Further investigation of (a) the 
retest reliability of the BPI-SF severity subscale; (b) the SF-MPQ-2 structural validity, known 
group validity, retest reliabilities, and responsiveness; and (c) the two questionnaires cross-
cultural validities, interpretability properties (MCID and CID), and measurement error indices 
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Full text articles excluded 
(n=66) 
Reasons (BPI-SF) = 28 
-No properties reported = 13 
-MSK participants (< 70%) = 7 
-Unclear pain population = 6 
-Review article = 2 
 
Reasons (SF-MPQ-2) = 38 
-Not SF-MPQ-2 used = 26 
-Unclear pain population = 6 
-No properties reported = 4 
-Review articles = 1 


























TABLE 1.  CHARACTERISTICS OF STUDIES ADDRESSING PSYHCOMETRICS OF THE BPI-SF AND SF-MPQ-2 
























Patients: Turkish speaking 
patients previously on routine 
outpatient physiotherapy                         
MSK distribution: 13.8% 
Upper extremity; 20.9% 
Lower extremity; 65.3% 
Spine 
 
Cross sectional N = 287 
Sex = Males, 26.9% 




Intervention: Usual care 
Retest: Baseline, general 
baseline & 7days, n=71-test-
retest. 
Group O. (1997)14 
Canada; 
Rheumatologist practice 
(Canada) and 4 




Patients: Patients who had at 
least one osteoporosis-
induced vertebral fracture 
with a clinical diagnosis of 




N = 226 
Sex = Females, 100% 
Age = 50yrs and above 
Responsiveness Intervention: Oestrogen 
replacement therapy; Cyclic 
Etidronate; Calcium; 
Calcitonin 












recruited had a history of 
chronic MSK lasting 2years 




N = 214 
Sex = Females, 66.1% 













Patients: Patients on wait-list 
for total hip replacement 
surgery and had satisfactory 




N = 250 
Sex = Females, 70% 




Floor or ceiling 
effect 
 
Intervention: Total hip 
replacement surgery 




5 primary care centres 
for Veteran in 
Indianapolis; 
BPI-SF (English) 
Source: Pooled data from a 
study on veterans with 
moderate to severe persistent 
musculoskeletal pain 
MSK distribution: 
Fibromyalgia, wide spread 
pain, pain at the joints, limbs, 
back and neck 
 
RCT N = 244 
Sex = Females, 83% 
Age = M, 55.1 yrs. 
Responsiveness Intervention: Not 
described 




10 primary care centres; 
BPI-SF (English) 
 
Patients: Patients had a 
primary diagnosis of 
osteoarthritis, rheumatoid 
arthritis, low back pain (on 
workers’ compensation) and 
Low Back Pain (not on 
workers’ compensation) 
 
Cross sectional N = 250 
Sex (not reported) 







Retest: Baseline and patients 
next follow-up visit 
Krebs (2009)22 and 
(2010)21 
USA; 
10 primary health 
centres; 
BPI-SF (English) 
Source: Pooled data from 3 
studies. The authors 
compared the responsiveness 
of 4 outcome measures 
MSK distribution: Majorly at 






N = 427 
Sex = 53.7% 





medication + Pain-self 
management VS 
Usual care 












Source: Pooled data from a 
registry designed to provide 
detailed prospective pain 
assessment of oxycodone 
users 
MSK distribution: Above 
70% of population with 
mixed chronic MSK pain 
including fibromyalgia, 
arthritis, back and neck pain 
Prospective 
cohort 
N = 741 
Sex= Females, 59.6% 
Age= M, 49.8 (SD 13.1) yrs. 












*focused on average 
pain and severity pain 
scores 
 
Source: Pooled data from 4 
RCTs. Participants all had a 
diagnosis of fibromyalgia 
and were randomized into 
control and placebo groups 
 
RCT N = 1411 
Sex = Females, 94.9% 





Intervention: Control group 
- duloxetine 
Placebo group – sham 





BPI-SF; 10 items 
Modified short form 
(English) 
 
Source: Pooled data from 2 
RCT studies. Participants 
suffering from Hip OA 
(study 1) and knee OA (study 
2) were recruited and 
randomized into control and 
placebo groups 
 
RCT N = 467 & 1019 
Sex = Males ≈ 35.3% 




Intervention: Valdecoxib + 
Naproxen 
Retest: Baseline, 1 week, 





*focused on average 
pain scale 
Source: Pooled data from 2 
RCT studies. Participants had 
knee pain in the last 3months 
for a duration of at least 14 
days/1-month 
 
RCT N = 524 
Sex = Females, 57.1% 
Age = M, 61 yrs. 
Responsiveness Intervention: Control 
NSAID + Duloxetine 
Placebo: Sham 









recruited had a diagnosis of 









N = 271 
Sex = Males, 119; Females, 
152 
Age = M, 57.1 (SD 16.2) yrs. 
Validity Intervention: None 
Retest: Baseline 
Stubbs (2015)47  
United Kingdom; 
10 elderly homes; 
BPI-SF (English) 
 
Patient: Older adults were 
surveyed in elderly homes on 
falls resulting from chronic 
MSK pain. They were 
divided into 2 groups: study 
group (with fall), and control 
group (without fall or MSK) 
to be compared 
 
Cross sectional  N = 298  
Sex = females ≈ 67.4% 
Age = M, 76.6 (SD 8.5) yrs. 




Chronic pain unit of 
Veteran affairs medical 
centre; 
BPI-SF (English) 
Patient: Participants were 
referred from several 
specialities, including 
surgery, rheumatology, 
physical medicine and 
rehabilitation 
MSK distribution: About 
50% reported pain of 
multiple sites (including back 
pain), and 28.8% reported 
primary back pain 
 
Cross sectional  N = 440 
Sex = Males, 91.8% 




Intervention: Usual care 








Source: Pooled data was 
from participants in a study 
of epidural steroid injections 
to alleviate low back pain 
RCT N = 37 
Sex (not reported) 
Age (not reported) 
Responsiveness Intervention: Epidural 
injection 







*Focus on interference 
scale 
Source: Pooled data from 2 
studies conducted on 
participants with a primary 
diagnosis of OA at any 
region and history of 
moderate to severe pain for at 






RCT N = 106 & 239 
Sex = Females, 62.5 & 
72.9% 







Retest: Study 1- 
Baseline, 7days, 14day; 
Study 2- Baseline, 
15,30,45,60, 90 days; Test 









Tertiary Pain & Rehab 
clinic; 
SF-MPQ-2 (Persian) 
Patient: Mixed sub-acute and 
chronic pain patients; 
Persian-speaking; 74-patients 
with diabetic neuropathic; 
184-patient with pain 
including myofascial pain, 
epicondylitis, knee and neck 
OA, Low back pain 
Cross sectional N = 258 
Sex = Female, 55% 






a.) Diabetic neuropathic 
patients: pre-gabalin, shoe 
modification education, and 
physiotherapy) 
b.) MSK patients: Physical 
therapy, Acupuncture, 
NSAIDS 
Retest: Baseline and 3-
weeks; Test-retest, baseline 
and 7-hours 
 
Dworkin (2014)11 & 
Turk (2015)51 
USA; 
Research setting of an 
RCT study, not 
specified; 
SF-MPQ-2 (English) 
Patients: Acute low back pain 
patients with radiating pain to 
at least one leg. Pain duration 
was within 30days 
RCT N = 664 
Sex= Males, 50% 








Retest: Baseline & 10days 
Kachooei (2014)17 
IRAN; 
Knee pain clinic; 
SF-MPQ-2 (Persian) 
Patient: Knee OA patients 
above 20years with a 
diagnosis of Knee pain for at 
least 6months. Knee OA 
confirmed via X-ray 
 
Cross sectional N = 100 
Sex = 80, Male; Female, 20 




Intervention: None  





clinics, Veteran Affairs 
Clinics, Primary care 




Patient: Mixed chronic pain 
population including MSK 
conditions like neck/joint 
pain (76%); low back pain 
(59%); Rheumatism (53%); 
and fibromyalgia 
Cross sectional N = 214 
Sex = 93%, Male 
Age = M, 54.4 yrs. 
Validity 
Reliability 






Two pain clinics, 
University Hospital 





Patients: Mixed Japanese 
speaking chronic pain 
patients 
MSK distribution: Knee and 
hip OA, lumbar and cervical 
radiculopathy 
Cross sectional N = 96 
Sex = Female, 51% 





Retest: Baseline & 3month 
Packham (2018)39 
NEW ZEALAND; 






Patients: English speaking 
adults with type-1 CRPS, as 
per, IASP classification, 
affecting any limb; no prior 
history of CRPS 
Longitudinal 
cohort 
N = 59 
Sex = Female, 72.9% 






Intervention: Not described 










Patients:  Patients had 
primary diagnoses of Knee 
OA.  Patients were excluded 
if they had surgery 3-months 
before the study 
Rasch analysis N = 255; Follow Up = 113 
Sex = Male, 42.4% 
Age = M, 68 (SD 9.6) yrs. 













TABLE 2: QUALITY OF STUDY REPORTS (ARRANGED HIGHEST TO LOWEST) 
 ITEM EVALUATION CRITERIA (SEE KEY BELOW) 
REFERENCED STUDY 1 2 3 4 5 6 7 8 9 10 11 12 Total (%) 
BPI-SF              
Lapane (2014)24 2 2 2 0 1 NA 2 2 2 2 2 2 86 
Stubbs (2015)47  2 2 1 0 2 NA 1 2 2 2 2 2 82 
Kapstad (2010)18 1 2 1 2 2 NA 2 2 2 2 1 1 82 
Keller (2004)20 2 2 2 2 1 NA 2 2 2 1 1 2 79 
Mease (2011)31 2 2 1 0 1 NA 1 2 2 2 2 2 77. 
Ferreira-Valente (2012)12 2 1 2 2 1 NA 1 1 2 2 1 1 73 
Williams (2006)55 2 1 1 2 1 1 1 1 2 1 2 2 70 
Song (2016)46 2 2 1 0 1 NA 2 1 2 1 2 1 68 
Celik (2017)4 1 2 1 2 1 2 1 1 2 2 0 1 67 
Tan (2003)48 2 1 1 1 1 NA 1 1 2 1 1 1 59 
Group O. (1997)14 0 2 1 0 2 NA 1 2 2 2 1 0 59 
Whynes (2013)54 1 1 1 0 0 NA 2 2 2 2 2 0 59 
Mendoza (2006)33 2 1 1 2 1 1 0 1 2 1 1 1 58 
Krebs (2009 and 2010)21,22 0 1 1 1 1 NA 1 1 2 2 1 1 55 
Kean (2016)19 0 2 1 0 1 NA 1 1 2 2 2 0 55 
Risser (2013)45 0 1 1 0 1 NA 0 1 2 2 2 0 50 
SF-MPQ-2              
Dworkin (2014)11 & Turk (2015)51 2 2 1 2 1 NA 2 2 2 2 2 2 92 
Lovejoy (2012)25 2 2 1 2 1 NA 2 2 2 2 2 2 91 
Packham (2018)39 2 2 1 2 0 NA 2 2 2 1 2 2 82 





Turner (2017)52 2 2 1 2 2 0 1 1 2 1 2 1 71 
Kachooei (2014)17 1 2 1 2 0 NA 2 1 2 2 2 0 68 
Adelmanesh (2012)1 1 2 1 2 1 0 2 1 2 1 1 1 65 
Percentage of studies that  
received 2 points per criterion 
 
54 67 12 54 16 33 41 41 100 62 58 34  
KEY: 
1. Thorough literature review to define research question                                                                 
2. Description of setting and participants (inclusion/exclusion criteria) 
3. Specific Hypothesis 
4. Appropriate scope of psychometric properties 
5. Sample size 
6. Follow-up/retention 
7. The authors referenced specific procedures for administration, scoring, 
and interpretation of procedures 
 
8. Measurement techniques were standardization and significantly void of 
bias 
9. Data were presented for each hypothesis 
10.  Selection of appropriate statistical test 
11. Use of benchmarks and confidence interval 
12. Valid conclusion and clinical recommendation 
 
Total score = (sum of subtotals ÷ 24 × 100). If for a specific paper an item is deemed NA (Not Applicable), then, Total score = (sum of subtotals ÷ (2 × number of Applicable items) × 
100)  


























95% confidence interval Cronbach alpha (α) coefficients: 
• Turkish version; Pain severity = 0.84; Pain interference = 0.89  







 • Pain severity = 0.85; Pain interference = 0.88  
(Tan et al.)48 
Mixed-MSK Very good + 
 • Pain severity and pain interference (Mood and activity) scales = 0.86 - 0.96 
(Mendoza et al.)33 
Mixed-MSK Adequate + 
 • Portuguese version; Pain interference = 0.91  
              (Ferreira-Valente et al.)12 
Mixed-MSK Very good + 
 • Pain interference = 0.82 - 0.89  
         (William et al.)55 
Specific-arthritis Very good + 
 • Norwegian version; Pain severity = 0.87; Pain interference = 0.88 
(Kapstad et al.)18 
Specific-Hip pain Very good + 
 • Arthritis patients; pain interference = 0.95; pain severity = 0.89 
(Keller et al.)20 
Specific- arthritis Very good + 
 • Lower back pain; pain interference = 0.93; pain severity = 0.82  
(Keller et al.)20 
Specific-back pain Very good + 
 Pooled evidence (range): BPI-SF severity and interference: 0.82-0.96, from 8 studies of very good to adequate quality 
GRADE of evidence: High 
Test- retest • Sample size (n)= 71; Stable on no treatment; retest interval=7days; ICC = 0.84, Interference; 
0.88, severity  
(Celik et al.)4 
Mixed-MSK adequate + 
 • Sample size (not specified); Patient status = assumed stable on medication; retest interval= 
daily, for 7 days: 
a. Pain severity, Pearson correlation(r)= 0.67-0.88. 
b. Mood-related Interference Pearson correlation (r) = 0.68-0.93. 







 • Sample size (n)=43; Assumed stable on high pain medication; 1 week interval (7days-14days): 
ICC =  0.81, interference (William et al.)55 
 
  





 a.) Pooled evidence: Severity subscale, n=71, ICC = 0.84, from one study of adequate quality 
GRADE of evidence = Low. 
b.) Pooled evidence (Weighted average): Interference subscale n=114, ICC = 0.83, from two studies of adequate quality 
GRADE of evidence = High 
Quality rating Key: + = Sufficient; - = Insufficient; ? = Indeterminate; NA = not applicable 




















Ceiling and floor effect • Floor effect – 1-year (After Total hip replacement): 24%, interference scale; 21%, Severity scale 
(Kapstad et al.)18 
 




Against Anchor – PGI-I 1/7 (among fibromyalgia patients) 
• BPI Severity scale: 2.79 (36.9% improvement) 












Against Anchor – PGI-I 1/7 (among fibromyalgia patients) 
• Severity = 2.16 points, (34.2% improvement) 






(i.) Known group validities 
 
 
Detected difference between: 
(a) Interference scale only: 
• Study 1 Pain-level (arthritis): Low to moderate pain, M, 4.68 (SD, 2.0); High pain, M, 6.6 (SD, 
1.9) (t130 = -5.66, P <0.0001)  















 • Study 2 Pain-level (Low back pain): Low to moderate pain, M, 5.36 (SD, 1.7); High pain, M, 6.33 








• Differentiate level of disability in Low back pain: stratified by ODI; discriminates between  
Mild, M, 1.61 (SD, 1.27) and Moderate, M, 3.20 (SD, 1.78);  
Mild, M, 1.61 (SD, 1.27) and Severe, M, 4.37 (SD, 1.69);  









• Disability (CMP older adults): AUC = 0.663; >4.5 (Fallers from non-faller); AUC, 0.684; Mean, 




Very good - 
 
 • Disability (CMP older adults): AUC, 0.724 (95% CI 0.630–0.818); Mean, 4.6 (Recurrent fallers 








 (b) Severity subscale only:  
• Disability (CMP older adults): AUC, 0.665; Mean, >5.1(fallers from non-fallers); AUC, 0.679, 







 • Disability (CMP older adults): AUC, 0.731 (95% CI 0.635–0.826); Mean, >5.1 (recurrent fallers 
from non-fallers) (Stubbs et al.)47 
 
Mixed-MSK Very good + 





Mild M,2.47 (SD 1.52) and moderate, M, 3.48 (SD, 1.63); mild, M, 2.47 (SD, 1.52) and severe, 
M, 3.94 (SD, 1.66); (p value 0.01 - 0.001)  
(note: failed to differentiate moderate and severe p-value = 0.089)   (Song et al.)46 
 
 (c) Interference and severity scale: 
• BPI-SF differentiates arthritis patients into varying pain severity as stratified on the 
Anchor CPG:  
Total scale MANOVA: F (6,182) = 17.58, P < 0.0001  
Severity ANOVA: F (3,92) = 19.01, P < 0.0001 










 • BPI-SF differentiates Low back pain patients into varying pain severity as stratified on the 
Anchor CPG: 
Total scale MANOVA: F (6,204) = 14.66, P < 0.0001;  
BPI Severity ANOVA: F (3,103) = 12.47, P < 0.0001;   
BPI Interference ANOVA: F(3,103) = 33.82, P < 0.0001(Keller et al.)20 
 
Specific-low back pain inadequate ? 
 Pooled evidence: 2 hypotheses confirmed in sufficient studies with “very good” quality rating. 
GRADE of evidence:  Moderate 
(ii) Convergent/ Criterion 
Validity 
Change in Predicted Direction: 
Change in BPI scores baseline to 7days, in concordance, with Patient global assessment of 
arthritis rating of change from baseline to 14 days) (Mendoza et al.)33 
 
Severity subscale: -2.35, Improved; -1.08, No change (CI 3.26 P < 0.001) 
Activity-interference subscale: 0.76, Improved; -2.32, No change (CI 2.56 P < 0.001) 








 Correlation with other scales reported as moderate (0.30-0.69): 
 
Severity subscale only: 
 















 • SF-36 (Physical function, mental, Role [emotional & physical], social function, vitality, general 




Very good + 
 




Interference subscale only: 
•      SF-12 Mental health and physical function, NRSP, HADP-Activity & Disability  









• WOMAC, (pain, stiffness, physical function, pain at night in bed), ALQ, sleep quality, number of 
night awakening (William et al.)55 
Specific-Arthritis 
 








(stiffness); SF-36 (role physical, role emotional, and general health) (Kapstad et al.)18 Specific-Hip OA 
 
Very good + 
 





Very good  + 
 
 Both Interference and severity scale:    
 • ODIc (Song et al.)46 Specific-Back pain 
 
Very good + 
 •       VAS (pain), WOMAC (pain, physical function and stiffness) (Mendoza et al.)34 Specific-Arthritis 
 
Very good + 
 
 •      FMI, SF-36 body pain (Krebs et al. 2009)22 Mixed-MSK Very good + 
 
 • WOMACn [Pain, Physical function); SF-36 (physical function, bodily pain, vitality, social 
function and mental function) (Kapstad et al.)18 
Specific-Hip OA 
 
Very good  + 
 
 • RMDQ-disability (Tan et al.)48 Mixed-MSK 
 
Very good +  
 
 Correlation with other scales reported as High (≥0.70): 
Interference subscale only:  
• SF-36 (Vitality, mental health, physical & social function), CGP-disability; RMDQ-disability  

















Very good  + 
 
 Severity subscale only: 








 Interference and severity subscale: 










 • PEG, Overall pain stress (Krebs et al. 2009)22 
 
Mixed-MSK Very good +  
 Pool evidence: 15 PROs examined: 94% hypothesis confirmed; 24 (64%) hypothesis @ rho, 0.3-0.69;10 hypothesis @ rho 
≥0.7 
Grade of evidence: high 
Structural validity; Factor 
Analysis 
 
Support 1 factor: 
• Confirmatory Factor Analysis; supports 1 factor structure (assessed only the Portuguese BPI-SF 
interference); χ2 (14) =72.54, (p < 0.001), CFI = 0.91; SRMR = 0.06; CFI = 0.91; SRMR 0.06 


















Support 2 factor: 
• Confirmatory factor analysis with principle promax rotation; 56% variance accounted; 2 factor 










 • Exploratory Factor analysis; principle promax rotation; 2 factor structure with 67% variance 
accounted; eigenvalues > 1 (6.9 and 1.2);interitem correlation 0.59-0.88 (Keller et al.)20 
 
Mixed-MSK Very good ?  
 • Compared a one, two & three factor model; 2 factor model (pain and interference) yielded best fit 
with CFI 0.99, CI 0.04-0.07. RMSEA for 2 factor model was 0.05 compares to 1 factor model 




Very good +  
 
 • Supports 2 factor structure; confirmatory factor analysis; yielded 2 factor models (pain and 
interference) with RMSEA 0.09, GFI 0.91, CFI 0.92; however, NFI - 0.89 and AGFI - 0.87  (> 










 • Confirmatory factor analysis; promax rotation; support two factor (interference and pain) 
accounting for 63.6% variance; eigenvalue 5.62 & 1.38 for interference and pain intensity 
respectively (Tan et al.)48 
 
Mixed-MSK Very good ? 
 Support 3 factor: 
• Modified version of SF-BPI; confirmatory factor analysis; Oblique rotation; 3 factor structures 
(pain, mood-interference and activity-interference); 86% variance accounted; eigenvalue range 
0.9 - 5.1; in both studies, items “sleep” and “enjoyment of life” did not load properly and were 








 Pooled evidence: “severity” and “interference” factor structures explained in 3 sufficient studies with “very good” quality 
GRADE of evidence: High  
Key: ODI, Oswestry Disability Index; PEG; 3-item SF-BPI (“pain average,” “interference with enjoyment of life,” and “interference with general activity”); CPG; Chronic Pain Grade; SF-36,Short Form-36 
Health Status Questionnaire; SF-12, Short Form-12 Health Status Questionnaire; RMDQ, Roland Morris Disability Questionnaire; FMI, Functional Morbidity Index; WOMAC, Western Ontario and McMaster 
Universities Osteoarthritis Index; HAD; Hospital Anxiety and Depression Scale; ALQ, Activities and Lifestyle Questionnaire; VAS, Visual Analogy Scale; NRS, Numerical Rating scale, CMP, Chronic 
Musculoskeletal Pain; t, Turkish; c, Chinese; pg, Portuguese version; n, Norwegian; AGFI, adjusted goodness-of-fit index; χ2, chi-squared; CFI, comparative fit index; df, degree of freedom; GFI, goodness-of-fit 
index; NFI, normed fit index; RMSEA, root mean squared error of approximation; SRMR, standardized root mean square residual; CI, Confidence interval; AUC, Area Under the ROC Curve; PGI-I, Patient 
global impression of improvement 
Quality rating Key: + = sufficient; - = insufficient; ? = indeterminate; NA = not applicable 



















Correlation of change scores Cross sectional change correlation (Group O.)14 
OQLD, physical= 0.72 and Symptom= 0.81 (baseline to 2 weeks) 
Longitudinal change correlation 








 Cross sectional change correlation(Whynes et al.)54 
BPI Severity: 0.52, 0DI; -0.59, EQ-5D-Index; -0.48, ED-5D-VAS 
BPI interference: 0.61, 0DI; -0.63, EQ-5D-Index; -0.40, ED-5D-VAS 
Similar pattern across other scales 
Weekly change correlation 
BPI Severity:  -0.57, EQ-5D-Index; -0.56, ED-5D-VAS; 0.70, ODI 
BPI Interference:  -0.58, EQ-5D-Index; -0.50, ED-5D-VAS; 0.65, ODI  











 Sensitivity to change in patient status (Krebs et al. 2010)21 
AUC (Any improvement): Severity = 0.81-0.83; Interference = 0.70 - 0.78 
AUC (Moderate Improvement): Severity = 0.81-0.85; Interference = 0.67-0.77 










 AUC (interference) = 0.80 (Whynes et al.)54 Specific-Back pain Very good + 
 Sensitivity to change in patient status (Kean et al.)19 
• AUC (Severity): 0.727, any improvement; 0.737, moderate improvement 
• AUC(total): 0.727, any improvement; 0.743, moderate improvement  








 • AUC (interference): 0.677, any improvement; 0.694, Moderate improvement. (Kean et al.)19 
 
Mixed MSK Very good - 
 Using MANOVA statistic, BPI significantly identified change in patients’ conditions (with 2-SEM 
signalling change on BPI) among:  
(a.) Arthritis (against HAD): [Wilks’ Lambda F(4,194) = 4.84, P < 0.001] 
(b.) Low back pain (against RMDQ): [Wilks’ Lambda F (4,198) = 10.77, P < 0.0001]  


















 BPI responsiveness to detect interventional change across visits; Interval (27.73 days)  





 1st visit 2nd visit 3rd visit T-test/CI 
BPI 
interference 
7.42 6.71 6.46 2.52-5.33 


























ES and SRM 
 
 
Improvement rating similar with RMDQ and PEG; higher than generic outcomes like CPG and SF 36- 
body pain.  









Sensitivity to change; anchor (patient reported global change- item 1/7) 3-months; compared to SF-36 
body pain, PEG and PROMIS PI-6b SF; PROMIS P-SF (27 and 57) (Kean et al.)19 
• SRM (Severity): Better, 0.71; Worst, -0.47; Same, 0.13 
• SRM (Interference): Better, 0.94; Worst, 0.03; Same, 0.38 



















 ES: Total RCT study = 0.64;  
       Back pain population = 0.60;  












ES: 0.53, BPI average pain item; Anchor, PRPI (0/10 scale); BPI average pain item similar to ICOAP 









12 months Responsiveness to intervention improvement in 2 different conditions 









Arthritis    
BPI Intensity -0.87 -0.55 0.01 
BPI Interference -0.84 -0.33 0.16 
Low back pain    



































BPI Interference -1.13 -0.56 0.43 
    
 
Specific- back pain Adequate ? 
  
 
• Magnitude of overall condition change (ES, SRM and RI), 12 months post THR (Kapstad et al.)18 
 
Indicators BPI interference BPI pain intensity 
ES 1.71 1.57 
SRM 1.52 1.61 












 • Magnitude of change on BPI scales; Anchor SF-36 perceived global change (1-7 scale); similarly 
responsive as WOMAC (physical and stiffness), and more sensitive than other SF-36 subscales in THR 
patient) (Kapstad et al.)18 
 






BPI Intensity 1.70 1.71 2.17 1.00 1.36 1.39 
       





















• Using Guyatt statistic, magnitude of change (BPI-Interference scale) between Control and Placebo 
(Williams et al.)55 
 
Intervals Study 1: ES Study 2: ES 
0-7days 0.46 - 
0-14days 1.06 - 
0-30days - 0.84 





















Pooled evidence: 5 reports with “very good” quality rating available on responsiveness of the BPI-SF  
GRADE of evidence: High 
Key: AUC, Area Under the ROC Curve; CGP, Chronic Pain Grade; WOMAC, Western Ontario and McMasters Universities osteoarthritis index; ICOAP, Intermittent and Constant Osteoarthritis Pain; PRPI, 
patient rated pain index; ; PEG, 3-item SF-BPI (“pain average,” “interference with enjoyment of life,” and “interference with general activity”); RMDQ, Roland Morris Disability Questionnaire; EQ-5D, 
European Quality of Life Instrument (Version 5D); PROMIS PI-6b-SF, short-form Patient-Reported Outcomes Measurement Information System-6b (Interference scale); ODI, Oswestry Disability Index; 
PROMIS P-SF (27 and 57), short-form-Patient-Reported Outcomes Measurement Information System Profile (29 and 57 item versions);SF-36,Short Form-36 Health Status Questionnaire; OQLD, Osteoporosis 
Quality of Life Questionnaire;  ES, Effect size; SRM, Standardized Response Mean; RI, Responsiveness Index 
Quality rating Key: + = sufficient;  - = insufficient; ? = indeterminate; NA = not applicable 



















Floor and ceiling effect: • Floor effect: Affective Scale, 15.1%; Neuropathic Scale, 12.5% (Dworkin et al.)11 Specific-Back 
pain 
NA NA 
 • Floor effect: Affective, 28.5%; Neuropathic , 12.4%; Intermittent, 15.1% (Lovejoy et al.)25 Mixed-MSK NA NA 
 • Floor effect: Continuous, 4.6%; Intermittent, 4.2%; Neuropathic, 1.9%; Affective, 8.7; Total, 3.1% 
(Adelmanesh et al.)1 





Correlation with other measures reported as moderate (Pearson or Spearman rho=0.3-0.69): 
Continuous scale: 















 • BPI severity (worst, least, average and current); NRS-average back pain, NRS-average leg pain; 
NRS-current back pain; NRS-current leg pain; HAD-total; HAD-anxiety  




Very good + 
 • MPI-interference; PDI; GAD-7; BDI-II (Lovejoy et al.)25 Mixed-MSK Very good + 
 • VASJ; SF-MPQJ (sensory, affective, total); LF-MPQJ (sensory, affective, evaluative, total)  
(Maruo et al.)29 
Mixed-MSK Very good + 
 Intermittent scale: 








 • BPI severity (worst, least, average and current); NRS-average back pain, NRS-average leg pain; 
NRS-current back pain; NRS-current leg pain (Dworkin, 2014 and Turk, 2015)11,51 
Specific-Back 
pain 
Very good + 
 • MPI-interference; MPI-Severity; PDI; GAD-7; BDI-II (Lovejoy et al.)25 Mixed-MSK Very good + 
 • VASJ; SF-MPQJ (sensory, affective, total); LF-MPQJ (sensory, affective, evaluative, total)  
(Maruo et al.)29 
Mixed-MSK Very good + 
 Neuropathic scale:  








 • BPI severity (least, average and current); NRS-average leg pain; NRS-current leg pain; HAD-
total; HAD-anxiety (Dworkin, 2014 and Turk, 2015)11,51 
Specific-Back 
pain 
Very good + 





 • VASJ; SF-MPQJ (sensory, affective, total); LF-MPQJ (sensory, affective, evaluative, total)  
(Maruo et al.)29 
Mixed-MSK Very good + 
 • CSS (Packham et al.)39  Specific-CRPS  Very good + 
 Affective scale:  








 • BPI severity (least and average); NRS-average leg pain; NRS-current leg pain, HAD-Total, 
HAD-Anxiety (Dworkin, 2014 and Turk, 2015)11,51 
Specific-Back 
pain 
Very good + 
 • MPI-interference; MPI-Severity; PDI; GAD-7; BDI-II (Lovejoy et al.)25 Mixed-MSK Very good + 
 • SF-MPQJ (sensory, total); LF-MPQJ (sensory, affective, evaluative, total) (Maruo et al.)29 Mixed-MSK  Very good + 
 Total scale:  








 • BPI severity (worst, least, average and current); NRS-average back pain, NRS-average leg pain; 
NRS-current back pain; NRS-current leg pain; HAD-total; HAD-anxiety  




Very good + 
 • MPI-interference; PDI; GAD-7; BDI-II (Lovejoy et al.)25 Mixed-MSK  Very good + 
 • VASJ; SF-MPQJ (sensory, affective, total); LF-MPQJ (affective, evaluative) (Maruo et al.)29 Mixed-MSK  Very good + 
 • CSS (Packham et al.)39  Specific-CRPS  Very good + 
 Correlation with other tools reported as High (Pearson or Spearman rho= ≥ 0.7): 
Continuous scale: 










 Affective scale: 







 Neuropathic scale: 







 Total scale: 







 • NRS-pain, PDI (Packham et al)39 Specific-CRPS Very good + 
 • VASP(Adelmanesh et al.)1 Mixed-MSK Very good + 





 Pooled evidence: 14 PRO Comparators; 75 Hypothesis, rho = 0.3-0.69; 6 Hypothesis, rho =  ≥ 0.7 
GRADE of evidence: High 
(ii.) Known group validity SF-MPQ-2 Total OR subscales: 
• Discriminant patient stratified by QTFC scale: 3, 4, & 6  
Only total scale score extracted 
QTFC category 3: total scale- M, 3.97 (SD, 2.03) 








 • Differentiate patients by number of reported pain sites, were those with higher SF-MPQ-2 pain 
scores indicated more pain sites.  
Only total scale score extracted:  
One pain site: M, 2.44 (SD 2.14);  
Two-three pain site: M, 2.97 (SD 2.13) 














 • Discriminate patients stratified on MPI scale into: 
Only total scale score extracted:  
None/mild: M, 1.16 (SD, 1.61) 
Moderate: M, 3.08 (SD 1.68)   











 • Differentiate patients stratified on PPI scale into:  
Mild pain: M, 33.81, (SD 14.16) p-value = 0.041  
Discomforting: 45.60 (SD 16.00) p-value = 0.028 
Distressing: M 53.62 (SD 18.78) p-value = 0.032  
Horrible: M, 58.49 (SD 18.97) p-value = 0.027 (Adelmanesh et al.)1 
 
Mixed-MSK inadequate ? 
 Pooled evidence: 4 hypotheses tested in studies with “inadequate” and “insufficient” quality rating. 




SF-MPQ-2 Total OR subscales: 
• SF-MPQ-2 Continuous scale: Item 8 and 9 misfit; item 10 displays uniform DIF for gender; passed 
unidimensionality test; removal of item 9 returns stability across structures; differential item 
functioning present among gender group 
• SF-MPQ-2 Intermittent scale: Passed unidimensionality test; items 2 and 3 misfit; No DIF for 
gender 
• SF MPQ-2 Neuropathic Scale: No item misfit; No dependency of item; scale passed 
unidimensionality test 
• SF-MPQ-2 Affective scale:  Item 15 misfit; passed unidimensionality test; items had disordered 



































• SF-MPQ-2 Total scale score: complete misfit with Rasch Model; several item exhibit dependence 
and don't exhibit differentially item function (Turner et al.)52 
 SF-MPQ-2 Neuropathic subscales: 
• Disorder ‘Tingling’ threshold corrected after collapsing to a 6-interval scale, from an 11-interval 
scale; passed unidimensionality test. 
• No item misfit; level of difficulty adequately distributed; acceptable Person fit statistics observed 
(x [SD] ¼ –1.17 [1.13] logits) 
• Although corrected, local dependence exhibited between “Burning” and “numbness” items; DIF 
observed on “Pain with light touch” item as severity level varies on the CSS scale. 
• Although corrected, person separation index below individual level of discrimination (0.78, against 
























Factor analysis Confirmatory Factor Analysis; hypothesized a four-factor Solution, 3 confirmed (Dworkin et al.)11 
• Continuous Scale; GFI, 0.988; RMSEA, 0.054; SRMR, 0.0268  
• Intermittent Scale; GFI, 0.957; RMSEA, 0.111; SRMR, 0.0459 
• Neuropathic Scale; GFI, 0.889; RMSEA, 0.191; SRMR, 0.0740 

















 • Confirmatory Factor Analysis; Compared a 1-factor, with a  4-factor solution; 4-factor solution 
demonstrates better fit; inter-item correlation 0.61-0.88 (Lovejoy et al.)25 
1-Factor Solution: TLI = 0.82, CFI = 0.84, SRMR = 0.06, RMSEA = 0.09, AIC = 19129 (poor fit) 















 • Exploratory  factor analysis; minimum loading factor 0.4; variance accounted 57.49% ; 4 factor 
solution supported; Heavy-pain item over load (Adelmanesh et al.)1 
Mixed-MSK Adequate ? 
 • Confirmatory factor analysis; 96 Subjects; Support a 4-factor solution; chi-squared= 478, degrees of 
freedom = 203; GFI = 0.917; AGFI = 0.894; RMSEA= 0.05) (Maruo et al.)29 
 
Mixed-MSK Inadequate + 
 Pooled result: 3 “very good” studies with conflicting evidence (-/+) 




Cronbach Alpha:               
• Total scalep: T1= 0.88 









 • Total scale: 0.93 




Very good + 
 • Total scale: 0.96 
• Subscales (Continuous, Intermittent, Affective, Neuropathic):  0.84 - 0.92 (Lovejoy et al.)25 






 • Total scoreJ: 0.907 
• SubscalesJ (Continuous, Intermittent, Affective Neuropathic): 0.857 -0.917) (Maruo et al.)29 
Mixed-MSK Very good + 
 • Total score: 0.95 
• Subscales (Neuropathic): 0.83 (Packham et al.)39  
 
Mixed-MSK Very good + 
 • Total scalep: 0.906 (Adelmanesh et al.)1 
 
Mixed-MSK inadequate - 
 Pooled evidence (range): SF-MPQ-2, range for total subscale= 0.88-0.96; range for Subscale score = 0.75-0.92, from 4 
studies of “very good” quality  





Intraclass correlation coefficients (ICC): 
• Analyzed with Rasch Model: 
• Normal ICC, for each subscale 0.38 - 0.67  











 • N = 43; Retest-interval = 3 days, 
• Total scale
p
 = 0.90;  
• Subscales
P








 • Total scale
P 
ICC = 0.941 (Adelmanesh et al.)1 
 
Mixed-MSK Doubtful + 





 (Continuous, Intermittent, Neuropathic, Affective): 0.75-0.85 (Maruo et al.)29 
 
Mixed-MSK Doubtful + 
 Pooled evidence: ICC range for Total score, 0.90; ICC range for subscales, 0.73-0.90, from one study of “adequate” 
quality 






• Post knee replacement patient; 6months interval. 
Effect Size: Continuous scale, 1.08; Intermittent, 1.12; Neuropathic, 0.15; Affective, 0.78 





 • Neuropathic subscale: Effect Size = 0.92 (CI, 0.53 -1.31); SRM = 0.97 (Packham et al.)39 
 





 • Change in patient status between baseline and day 5, after commencement of treatment was significant 
for all subscales of the SF-MPQ-2 and its total score (Dworkin et al.)11 
 
Subscale         Baseline  
        M(SD) 
Day-5   
M(SD) 
T-Test value 
continuous 5.19 (2.19)  2.79 (2.13 t(527) = 26.36, P < .01 
Intermittent 5.04 (2.34)  2.45 (2.15 t(527) = 27.75, P < .01 
affective 2.94 (2.26)  1.47 (1.69) t(527) = 17.73, P < .01 










 • Non-neuropathic patients mean difference of pre-treatment and Post-Treatment as anchored with 
PGIC (Adelmanesh et al.)1 
Subscale         M(SD) P-Value 
Very much improved 
 
35.20 (SD 11.43) 0.007 
Much Improved 
 
28.22 (SD 8.62) 0.0014 
Minimally improved 
 
21.43 (SD 5.40) 0.016 
No change 9.33 (SD 6.08) p-value not 
reported 
   
 
 
Mixed-MSK Inadequate - 
 Pooled evidence: `1 adequate study of indeterminant quality 
GRADE of evidence:  Very low 
 
Key: WOMAC, Western Ontario and McMaster Universities Arthritis Index; SF-36,Short Form-36 Health Status Questionnaire (PF=Physical Function, BP=Body Pain, 
GH=General Health, VT=Vitality, RE=Role Emotion, MCS=Mental Component Summary, PCS=Physical Component Summary); QTFC, Quebec  Task Force 
Classification for Spinal Disorder; MPI, Multidimensional Pain Inventory; CI, confidence interval; CSS, Complex Regional Pain Syndrome Severity Score;  PDI, Pain 
Disability Index; BDI-II, Beck Depression Index-Version 2; GAD-7, General Anxiety Disorder 7-item scale; SF-MPQJ, Short form McGill Pain Questionnaire-Japanese 
Version; LF-MPQJ, Long Form McGill Pain Questionnaire-Japanese version; PPI, Present Pain Intensity; AIC, Akaike Information Criterion; VAS, Visual Analogy 
Scale; HAD; Hospital Anxiety and Depression Scale; NRS, Numerical Rating scale; PGIC,  patient global impression of change; AGFI, Adjusted Goodness-of-Fit 
Index; CFI, comparative fit index; GFI, goodness-of-fit index; RMSEA, root mean squared error of approximation; SRMR, standardized root mean square residual; M, 
Mean; SD, standard deviation CFI comparative fit index; TLI; Tucker-Lewis index; P, Persian version; J, Japanese version 
 
Quality rating Key: (+) = sufficient; (-) = insufficient; (?) = indeterminate; NA = not applicable 












Brief Pain Inventory-Short form 
 
Revised short McGill Pain 
Questionnaire Version 2 
 









Subscales and Total scores 
1. Test-retest reliability 
 
High (+) Low (+) Low (+) Yes, BPI-SF 
3. Internal consistency 
 
High (+) High (+) High (+) No 
4. Responsiveness 
 
High (+) High (+) Very low (?) Yes, BPI-SF 
5. Structural validity 
 
High (+) High (+) High (+/-) Yes, BPI-SF 
6. Hypothesis testing 
(convergent validity) 
 
High (+) High (+) High (+) No 
7. Hypothesis testing 
(known group validity) 
 
Moderate (+) Moderate (+) Very low (?) Yes, BPI-SF 




No evidence No evidence No evidence No evidence 
9. Measurement error 
(SEM and MDC) 
 
























Search concepts adapted, each for the BPI-SF and SF-MPQ-2, on Medline, EMBASE, 
CINAHL and Scopus bibliographic databases 
A. (“Brief Pain Inventory”) AND (Psychometric OR “Measurement Properties” 
OR Validation OR Adaptation OR "Cross-cultural" OR Reliability OR Validity 
OR "Internal Consistency" OR Sensitivity OR Specificity OR Discriminative 
OR Responsiveness OR "Factor analysis" OR Minimal Clinically Important 
Difference OR "Clinically Important difference" OR Rasch) 
 
B. ("McGill Pain Questionnaire") AND (Psychometric OR “Measurement 
Properties” OR Validation OR Adaptation OR "Cross-cultural" OR Reliability 
OR Validity OR "Internal Consistency" OR Sensitivity OR Specificity OR 
Discriminative OR Responsiveness OR "Factor analysis" OR Minimal 
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Study design: Test-retest. 
Background: The Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2) is a 
multidimensional outcome measure designed to capture, evaluate and discriminate pain from 
neuropathic and non-neuropathic sources. A recent systematic review found insufficient 
psychometric data with respect to musculoskeletal health conditions.  
Objectives: To describe the reproducibility (reliability and agreement) and internal 
consistency of the SF-MPQ-2 for use among patients with musculoskeletal shoulder pain. 
Methods: Eligible patients with shoulder pain completed the SF-MPQ-2 two times: at 
baseline (n=195), and after 3-7days (n= 48), if they remained in stable pain. Cronbach alpha 
(α) and intraclass correlation coefficient (ICC2,1), and their related 95% CI were calculated. 
The Standard Error of Measurement (SEM), group and individual minimal detectable change 
(MDC90) and Bland-Altman (BA) plots were used to assess agreement. 
Results: Cronbach α ranged from 0.83 to 0.95 suggesting very satisfactory internal 
consistency across the SF-MPQ-2 domains. Excellent ICC2,1 scores were found in support of 
the total (0.95) and continuous scale (0.92); the remaining domains displayed good ICC2,1 
scores (0.78 -0.88). The Bland-Altman analysis revealed no systematic bias between the test 
and retest scores. While the best agreement coefficients were seen on the total scale (SEM = 
0.5; MDC90 = 1.2 and MDC90group = 0.3), they were acceptable for the SF-MPQ-2 
subscales (SEM: range, 0.7 - 1; MDC90: range, 1.7 - 2.3; MDC90group: range, 0.4 – 0.5).  
Conclusion: Good reproducibility supports the SF-MPQ-2 domains for augmented or 
independent use in MSK-related shoulder pain assessment, with the total scale displaying the 
best reproducibility coefficients. Additional research on the validity and responsiveness of 
the SF-MPQ-2 is still required in this population. 
Keywords: Reproducibility; Reliability; Agreement; McGill Pain Questionnaire; Shoulder 







Shoulder disorders are among the three leading causes of musculoskeletal pain.29,35 
Although present in all age groups, there is evidence of its increasing prevalence as age 
increases.9,32 Shoulder disorders come with significant consequences on the socioeconomic 
wellbeing of the patient and the society; studies have linked workers’ absenteeism, loss of 
job, and poor health-related quality of life (HRQoL) to symptoms associated with shoulder 
disorders.9,23,28,42,56  
Pain assessment in clinical practice and research often places emphasis on monitoring 
pain intensity, even though we know pain is multidimensional and experienced uniquely by 
individuals.37 Patients perceive pain in 6 multiple dimensions: physiologic, sensory, 
affective, cognitive, behavioral and socio-cultural.3,37 The comprehensive assessment and 
monitoring of these dimensions should improve patient care.24 A multidimensional pain 
assessment tool that provides a holistic assessment of pain has been recommended by 
experts4,19,59 for use in upper extremity conditions, including shoulder disorders. 
The Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2) is an example 
of a general use multidimensional pain tool that comprehensively examines the sensory and 
affective dimensions of pain. Dworkin and colleagues14 added seven new items to the former 
15 items SF-MPQ to enhance the SF-MPQ-2 ability to explicitly examine both neuropathic 
and non-neuropathic pain characteristics. They also replaced the previous 4-point descriptive 
rating scale with a 10-item numerical rating scale to enhance its responsiveness.14 Since then, 
multiple studies have utilized the improved SF-MPQ-2 as a primary outcome for pain 
assessment in clinical trials, and its measurement properties have been examined in different 
populations including cancer pain,18 surgical pain,43 visceral pain,58 and neuropathic pain.40 
Among MSK conditions, studies have reported measurement evidence examined among 
patients with complex regional pain syndrome,45 back pain,15 knee OA,26 and mixed MSK 






review25,31 reported on evidence with design flaws including inadequate description of ICC 
models, insufficient justification of retest interval, and lack of attention to absolute reliability 
parameters.  
In the absence of such evidence, the primary purpose of this study was to investigate 
the reproducibility (test-retest reliability and agreement) and internal consistency of the 
Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2) among persons with MSK-
related shoulder problems. 
METHODS 
This study was based on a test–retest design. The SF-MPQ-2 questionnaire was 
administered to examine reproducibility (i.e. relative and absolute reliabilities and internal 
consistency) at two time points: at baseline and after 3-7 days (when patients would, for the 
most part, be stable).12,34 The participants were recruited from the Roth|McFarlane Hand and 
Upper Limb Center, London, ON, Canada over a period of 6-months (June – November 
2018). Ethical approval to recruit and review patients’ clinical charts was waived by the 
Health Sciences Research Ethics Board of the University of Western Ontario, London, 
Ontario, Canada. 
Patients 
Adults proficient in English, above 18 years of age, that experienced pain from one or 
more shoulder conditions of known MSK source were included. Potential participants were 
excluded if they had: 1) an unstable cardiorespiratory condition; 2) any history of problems 
relating with the central nervous system e.g. hemiplegia; 3) pain resulting from neoplastic or 
infectious or vascular disorders or referred from internal organs; 4) any neuropathic pain 
symptoms resulting from thoracic outlet syndrome, carpal tunnel syndrome or any peripheral 








Assessors (SJ and HULC research assistants) identified potentially eligible 
participants by reviewing the outpatient appointment list of patients scheduled for a clinical 
visit with two shoulder surgeons (KF and AG), a day prior. Potential participants were then 
contacted on the day of their clinical appointment to see whether they would be willing to 
participate. Consenting persons were screened to ensure all criteria were satisfied, then they 
received further explanation of the study’s aims and objectives before the SF-MPQ-2 
questionnaire was administered. Each participant was verbally instructed to carefully read 
and circle the one number that described their pain experience. In cases where participants 
had difficulty with selecting an answer, they were told to choose the answer that comes 
closest to describing their pain symptoms. If help was needed with understanding any words 
or phrases, or with marking their responses, the assessors assisted. The participants were 
instructed to complete all items in the questionnaire. Participants were permitted to withdraw 
from the study for any reason at any time. A subset of the participants were randomly 
selected to self-complete the SF-MPQ-2 at home after 3-7 days if their pain remained 
unchanged. Participants were given stamped envelopes (if they accepted) and instructed to 
return the completed questionnaire. A global rating of change scale was administered on both 
test-retest occasions and compared to ensure that we only reported on patients with stable 
pain (for test-retest). Demographic information including age, hand dominance, primary 
cause of shoulder pain and gender were noted in person and from their clinical record. 
Outcome Measure 
The Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2) contains 22-
items/pain descriptors and 4 subscales/domains that examine pain intensity and quality as 
follows: (i) continuous  pain  (throbbing, cramping, gnawing, aching, heavy, and tender 
pain); (ii) intermittent pain (shooting, stabbing, sharp pain, splitting pain, electric-shock, and 






itching, tingling or pins and needles, and numbness pain), and (iv) affective pain (tiring-
exhausting, sickening, fearful, and punishing-cruel). All the items are bounded on a zero 
(none) to 10 (worst possible) numerical rating scale. The mean of the 22-items yields the SF-
MPQ-2 total score, while the mean of the items that comprise each of four-subscales yields 
the summary score for the subscale.14,15 Higher subscale or total scores suggest greater pain 
symptoms/experience, and more than 2 missing values renders patients’ response to the 
questionnaire invalid.15 The SF-MPQ-2 uses a recall period of 7-days, instructing the person 
to base their rating on their symptoms in the past week.13 
Statistical analyses  
The SF-MPQ-2 total and subscale scores were considered as interval variables. Data 
quality and screening, including the percentage of missing data, outliers, and presence of 
floor/ceiling effects was performed. Respondents with two or more missing items were 
excluded, in line with the developers’ instructions.15 Continuous variables were descriptively 
summarized using means and standard deviations while percentages were used to report 
categorical variables. The data was then examined for normality graphically with histograms, 
and statistically with the Shapiro-Wilk test. All statistical analysis were completed with 
Microsoft Excel Version 2013 and SPSS statistic for windows, Version 25.0. (Armonk, NY: 
IBM Corp, Released 2017).  
Floor/ceiling effects 
The SF-MPQ-2 was assessed for floor/ceiling effect by identifying the number of 
participants with the absolute lowest (0-points = floor) and highest scores (10-points = 
ceiling) on its total and subscales. Floor/ceiling effects occurring at the magnitude of 15% 
were considered substantial.52 
Hypothesis: We expected substantial floor effects on the neuropathic and affective 
subscales of the SF-MPQ-2 because they evaluate pain dimensions that are relatively 






Cross sectional reliability (Internal consistency) 
Internal consistency, the degree of item inter-relatedness/equivalence in a 
PROM,11,51,52 was assessed with Cronbach alpha (α) and associated 95% confidence 
intervals. A commonly accepted requirement for internal consistency reliability is that it 
should be at above 0.7. However,  redundancy was established at α > 0.95.50–52 
Hypothesis: We expected the SF-MPQ-2 to be internally consistent with Cronbach 
alpha (α) at 0.8 or above for its subscale scores, and 0.9 or above for its total scores. 
Relative reliability (Test-retest reliability) 
The intraclass correlation coefficient (ICC2,1) was used to assess the retest reliability 
of the SF-MPQ-2 total and subscales.48 ICC2, 1 with 95% confidence interval (CI) were 
computed using the two-way mixed and absolute agreement model, that assumes the patients 
were randomly selected but the occasions were fixed choices.47 We chose ICC2,1 absolute 
agreement over consistency model because it captures elements of systematic bias and is 
preferred for computing absolute reliability indicator. ICC2,1 values for the SF-MPQ-2 total 
and subscale scores were considered Negative ≤ 0.49, Doubtful 0.50–0.69, Good 0.70–0.89, 
and Excellent 0.90–1.00.36  
Hypothesis: We expected adequate ICC2,1 scores for group level analysis at ≥ 0.80 
(total score), and ≥ 0.70 (subscale score) as previously reported in the literature.1,26  
Absolute reliability (Standard Error of Measurement [SEM] and Minimal Detectable Change 
[MDC]) 
 Standard Error of Measurement (SEM) is defined as the standard deviation of errors 
of measurement associated with particular test takers scores.22  Table 1 explains the five 
equations used for agreement analysis. To define SEMagreement for the SF-MPQ-2 total and 
subscales scores, the pooled standard deviation calculated from participants mean responses 






non-transformed ICC2,1 for the SF-MPQ-2 domain under evaluation was keyed into equation 
222,44,57 (Table 1). Further, the proportion of the resulting SEM per domain to the total score 
of the scale was calculated to yield the SEM percentage or SEM%, as previously used5,44,49 
and interpreted as follows: ≤5% = very good;  >5% to ≤10% =  good;  >10% to <20% = 
doubtful; and values above 20% = negative44       
The minimal detectable change (MDC) or repeatability coefficient describes the 
minimum amount of change that must be seen on a tool scores to be confident that true/real 
change has occurred without error after two repeated measure, within the period of the test-
retest.21 For this study, a 90% confidence interval was estimated for the Minimal Detectable 
Change (MDC90). Like the SEM, it is also expressed in the unit of the measure and may be 
computed at an individual level (MDC90individual) or for a group (MDC90group)
12. We estimated 
MDC90individual for the total and subscale scores of the SF-MPQ-2 by entering each scales 
SEMagreement into equation 3 (Table 1) assuming the data was normally distributed and free 
of systematic error. The MDC90individual confidence interval was then computed from the mean 
differences (d) of each subscale using equation 4 (Table 1)5,10,12 To determine the group 
level minimal detectable change (MDC90group), which is useful for determining if changes 
have occurred in an entire population, equation 5 (Table 1) the formula proposed by de Vet 
et al.52,55 was employed. Furthermore, as was estimated for SEM, the proportion of the 
resulting MDC coefficient per SF-MPQ-2 domain to the total score of the scale was 
computed, as previously done,5,44 to yield the MDC percent score (MDC%) and interpreted 
was follows: ≤5% = very good; >5% to ≤10% =  good;  >10% to <20% = doubtful; and 
values above 20% = negative.44 
Bland-Altman Plots (BA Plots): 
The Bland-Altman method was used to visually examine the agreement between the 
test and retest scores.6,7 Scatter plots for the total and subscales scores were each plotted for 






against their mean score for the two time points.6–8,41 We then calculated the mean difference 
between the two measurement intervals (the ‘bias’) and the 95% limits of agreement (LOA) 
using: LOA = mean difference (d) ± 1.96 SD of the mean differences. The BA plots were 
used to visually judge the 95% limits of agreement to determine how well score from 
repeated measurements agreed: narrower LOAs suggested better agreement at the individual 
level.12,17,41 Agreement at the group level was determined by how close the bias (mean 
difference) was to zero. Also, the distribution of scatter points on the BA plots were visually 
scrutinized for evidence of variability or heteroscedasticity, where the absence of a linear 
relationship between test-retest mean differences and their mean scores, per subscale, suggest 
the absence of systematic bias.6–8,41,54,55 Furthermore, linear regression models were used to 
explore the presence of systematic bias. For each domain of the SF-MPQ-2, mean scores and 
differences in mean scores were modelled as the independent and dependent variables, 
respectively. The presence of systematic bias was confirmed by a significant prediction of the 
differences by the means scores.41,53 Finally, outliers that presented beyond the upper and 
lower boundaries of the LOA were noted and explored.12,16 
RESULTS 
Figure 1 summarizes the flow of participants through the different phases of the 
study. Of the 238 potential patients identified from the review of scheduled appointment list, 
195 consenting adults that satisfied the inclusion criteria, provided complete data that was 
considered in our analysis of cross-sectional reliability. For the analysis of relative and 
absolute reliability, 48 out of 55 stable patients returning completed copies of the SF-MPQ-2 
did not have missing data; the mean duration for retest response was 4 days. Table 2 
summarizes the characteristic and demographic distribution of the baseline population. 
Persons completing this study could be described as an older population, (mean age = 62 






different shoulder problems of various MSK pathologies including rotator cuff injuries, 
humeral fracture and arthroplasty, and shoulder pain. 
Both the graphical and statistical tests of normality revealed the dataset was 
skewed/abnormal. To address the assumption of normality for further analysis, a square root 
calculation was used to transform the data. A closer look at the reliability coefficients 
obtained using the transformed and untransformed data revealed only a very trivial difference 
in scores. Because our sample size was large enough, and beyond 30 participants (based on 
the central limit theorem), parametric statistics were adopted in our analysis. Despite that, we 
still checked for differences in reproducibility coefficients obtained using the transformed 
and non-transformed ICC scores (see Table 3 for results). 
Floor and ceiling effects 
The presence of floor/ceiling effect may suggest an outcome measure is not 
responsive to detecting improvement (ceiling effect) even though decline in status can be 
captured, and vice versa – for floor effects.15 The number of patients who obtained the 
absolute maximum (Ten, 10) and minimal (zero, 0) scores on the SF-MPQ-2 total and 
subscales are summarized in Table 3. The greatest level of floor effects was observed on the 
affective subscale at both periods of the test-retest. Substantial floor effects were also noted 
on the neuropathic and intermittent subscales. None of the SF-MPQ-2 indices had 
remarkable ceiling effects. 
Reliability 
Internal consistency (cross-sectional reliability) 
Table 4 summarizes the result obtained for cross sectional reliability. The SF-MPQ-2 
displayed excellent internal consistency with robust alpha coefficients presenting within a 






at 0.95 as posited, while that for the subscales fluctuated around 0.83 to 0.86 points. Inter-
item correlations were satisfactory, ranging from 0.23-0.53 across the scales. 
Relative Test-retest reliability 
Good to excellent results were seen in support of test-retest reliability of the SF-
MPQ-2 domains (Table 5).  Our results for ICC2,1 was based on analysis conducted with the 
non-transformed data, as they did not differ from that obtained with transformed data. ICC2,1  
scores were highest on the continuous and total subscales and rated excellent according to 
our criteria. Also, the neuropathic, affective and intermittent subscales displayed good ICC2,1 
coefficient (Table 4) in support of relative reliability. 
Absolute test-retest reliability (agreement parameters) 
Table 5 summarize the absolute reliability coefficients supporting the SF-MPQ-2 
domains. The total scale SEMagreement  was very low (0.51points) and approximately 5% of the 
total score of the scale, which is ‘very good’ according to our criteria. Individual subscale 
SEMagreement  ranged from 0.73 -0.99 (approximately ≤ 10 % of the total score), which is 
‘good’ according to our criteria. At the individual level, acceptable scores within 1.19 – 2.29 
points were seen in support of minimal detectable change at 90% confidence level. The best 
and worst scores were noted on the total scale (1.19 point, i.e. 11.9% of the total score) and 
the intermittent subscale (2.29 point, i.e. 22.9% of the total score), respectively. For Group 
MDC90, estimates were acceptable and expectedly lower than those obtained for 
MDC90individual; the results fluctuated within 0.28 (total) to 0.54 (intermittent) points across 
the SF-MPQ-2 domains (Table 5). 
Bland-Altman Analysis/Plots 
The results of our Bland–Altman analysis are presented in Table 4. Also, Bland-






of the SF-MPQ-2 are graphically illustrated (Figure 2 to 6). All the SF-MPQ-2 domains 
displayed acceptable LoA at 95% confidence level with the highest distance ranging 5 points 
(intermittent subscale). The total scale score displayed the narrowest LoA (range = 3 points), 
with the remaining subscales within satisfactory limits. Mean difference scores (bias) were 
very acceptable for all the SF-MPQ-2 domains (0.15 – 0.19 points). 
Visual inspection of scatter points on the BA plots for each domain of the SF-MPQ-2 
revealed that the magnitude of mean difference against the mean scores were uniformly 
distributed from the point of zero and most scatter points were within the 95% Limit of 
Agreement but for few outliers. This supports the absence of systematic bias and suggest a 
good level of agreement among test-retest scores. Furthermore, for each of the SF-MPQ-2 
domains, there was no evidence of the mean difference scores predicting the mean average 
after our regression model analysis. This gives more weight to the absence of systematic bias 
and confirms good level of agreement between the test-retest scores (Table 5).   
The few outliers noted were explored. First, we determined if they were erroneous 
responses in entry by rechecking hard copies but, indeed, they were ‘interesting’ outliers 2 
and labelled according to their #RS on each BA plot. The greatest number of interesting 
outliers presented on the intermittent (n=6, 12.5%) and neuropathic (n=4, 10%) subscales. 
The least number of outliers were seen on the affective subscale (n=2, 4.1%). In general, 
however, the presence of these outliers did not indicate the presence or absence of bias.2 
DISCUSSION 
This study provides strong support of the reproducibility of the SF-MPQ-2 for use in 
multidimensional pain assessment of people with musculoskeletal shoulder pain. We found 
good to excellent reproducibility coefficients in support of internal consistency, relative 
reliability and absolute reliability. The limits of agreement for the subscales and total scores 






Although some floor effects can be expected on the neuropathic, intermittent and 
affective subscales, we attribute this to the lower prevalence of these problems in our 
populations and the high discriminative property of the SF-MPQ-2 subscales. Conceptually, 
the SF-MPQ-2 was expanded to provide a single tool that can classify pain from both 
neuropathic and nociceptive sources.14,15 As outcome measures can be evaluative or 
discriminative, combining both purposes within an outcome measure is likely to result in 
these type of issues. For instance, participants with pain emerging from neuropathic sources 
are more inclined to respond adequately to the neuropathic subscale with no floor effect, as 
has been observed with the use of the SF-MPQ-2 among CRPS patients.45 This implies that 
floor effects on the SF-MPQ-2 domains may not always represent redundancy but may 
suggest that an item does not describe the patient’s pain experience.25 
Cross sectional reliability was established for the SF-MPQ-2 total and subscale scores 
with satisfactory coefficients supporting internal consistency in line with previous estimates 
among mixed-MSK30 (total, 0.93; subscale, 0.84-0.92), CRPS45 (total, 0.95; neuropathic 
subscale, 0.83), knee OA26 (total, 0.88; subscale 0.75-0.81) and acute back pain15 (total, 0.93; 
subscale, 0.77-0.84) patient populations. Inter-item correlations were also adequate. The 
adequate Cronbach's alpha obtained signifies the absence of redundancy in the domains of 
SF-MPQ-2 thus confirming their unidimensionality51 to capture the different pain 
characteristics they assess. 
In the present study, ICC2,1 coefficients were good to excellent for all the SF-MPQ-2 
domain scores (total, 0.93; subscales, 0.78 - 0.91), suggesting they can discriminate patients 
adequately at the individual level (total and continuous scale), and at the group level (all the 
SF-MPQ-2 domains).12,27 These results are comparable or better than previous findings 
reporting estimates among knee OA26 (total, 0.90; subscale, 0.73-0.90) and mixed MSK 
patients1,33 (total, 0.90-0.941; subscale, 0.73-0.90). Although acceptable, the low 






‘moderate’ confidence interval threshold suggest less variability on this subscale which 
makes it more difficult to achieve a high ICC2,1 score. 
Absolute reliability estimates allow clinicians to assess true change in a patient in 
comparison to change that might be expected from measurement error.52,55 Currently, no 
previous data have examined absolute reliability indices for the SF-MPQ-2 scores in any 
population. This makes direct interpretation and comparison difficult; however, our use of 
Ostelo et al.44 definition of SEM and MDC by percentages allows comparison across the 
domains of the SF-MPQ-2, and with its former version (SF-MPQ). The SEM for the total 
score (≤ 5% of total scale score) was ‘very good’ and comparable to that reported for the 
former version (SF-MPQ) among OA patients (≤ 3.64%)20 but better than those seen among 
mixed MSK patients assessed with the Norwegian version of the SF-MPQ (≤ 10%).49 
Although not as favorable as estimates noted on the total subscale, the affective and 
intermittent/continuous (or sensory subscale on the previous version) subscales displayed 
‘good’ SEM (≤ 10%) that was similar to that seen among OA patient (≤10%)20 or better than 
those seen among mixed MSK (≤14%)49 with the previous SF-MPQ version. Basically, SEM 
estimates for all the SF-MPQ-2 subscales were satisfactory and suggest an adequate 
evaluative capacity that can yield scores less prone to error when utilized by 
researchers/clinicians for MSK shoulder pain assessment over time. 
The MDC scores represents the minimal change in scores after repeated 
administration that clinicians/researchers can interpret is not due to error for an individual or 
group in a population.21 The MDC90indivdiual scores obtained for the SF-MPQ-2 domains 
implies that change at a magnitude equal or greater than 1.8 (neuropathic), 1.7 (affective), 1.8 
(continuous), 2.3 (intermittent), 1.2 (total) points represents genuine improvement beyond 
error with 90 percent confidence. The MDC scores for the total scale (≤ 11.9% of the total 
score of the scale) were comparable to previous studies with the former version (SF-MPQ) 






26.4% of total score). The MDC90group means that change of atleast 0.4 (affective), 0.5 
(intermittent), 0.3 (total), 0.4 (neuropathic), 0.4 (continuous) points must be noted for a group 
to be 90-percent confident that it is change beyond random or systematic error. In general, 
MDC scores are useful when interventions are administered: to be sure the intervention is 
effective, it must demonstrate change beyond the MDC score reported for the scale. Also, 
MDC90group indices can be used for sample size estimation in a randomized controlled trial, as 
they determine the number of participants that will be needed to detect a change on the 
measure beyond error for a group, if the Minimal Clinical Important Difference score for the 
population is unknown. 
The Bland-Altman plots revealed very satisfactory LoA in support of the SF-MPQ-2 
subscales. Although the interpretation of how far apart two measurements can be before they 
are no longer considered interchangeable depends on the contextual application,41 the LoA 
between test-retest of the SF-MPQ-2 domains were reasonably smaller than those seen in 
previous studies with its  former version (SF MPQ)20,49 and suggest minimal variation 
between the occasion of test-retest.54 Furthermore, no bias was found in measurement 
between the test-retest, since the inter-occasion mean difference was minimal. This suggests 
that learning or test accommodation are not issues with using the SF-MPQ-2; moreover, our 
compliance to recommended time intervals (3-7 days)12,34,38 may have favored the agreement 
outcomes. The intermittent subscale had the greatest number of outliers of all the BA plots 
(12.5%) and may be from the highly volatile nature of the pain descriptors comprising the 
scale.  
The SF-MPQ-2 total scores displayed the best reproducibility parameters in support 
of its relative, absolute and level of agreement parameters. This could be from the number of 
items contained in the scale. For instance, better ICC scores can be expected when variability 






comprise a scale, in comparison to those with fewer descriptors.12 As all 22 items of the SF-
MPQ-2 contribute to the summary total scale scores, it is possible this favors reproducibility. 
STUDY LIMITATIONS AND AREAS FOR FUTURE RESEARCH 
While the present study findings provide preliminary evidence supporting the 
reproducibility of the SF-MPQ-2 for use in shoulder problems, it has several limitations. 
First, the study sample size (48 participants) was just under 50 participants as recommended 
by the COSMIN.39,46 Second, the patient population were from a single tertiary referral 
practice, hence our findings may not be the same in a less differentiated cohort; it may also 
impact on generalizability. Third, since participants completed the retest (Time 2) at home, 
we were unable to clarify instructions. However, independent completion is a requirement for 
routine administration. Further, the high level of agreement between scores of the tests and 
the absence of systematic bias suggest this was not a problem. Fourth, sample mean age was 
62 (+ 17.3) years, which may not adequately reflect the reliability of younger populations. 
Finally, we did not determine minimal clinically important difference. 
CONCLUSION 
We conclude that the SF-MPQ-2 provides good to excellent test-retest reliability for 
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(n = 102) 
 
Potential Participants Identified 
from Surgeons Appointment 
schedules and EMR Chart 
                (n = 238) Did not meet predefined inclusion 
criteria: 
1. Did not consent to participate (n= 10) 
2. Not English speaking (n = 5) 
3. Severe cardiovascular disorder (n = 4) 
4. Inpatient booked for surgery (n=11) 
Figure 1: Flow chart of progress through the phases of screening, recruitment, test, retest and data analysis. 
Participant that completed  the 
SF-MPQ-2 at baseline (Time 1)  
(n=208) 
Participants for 
Reproducibility Analysis   
(n=195) 
Excluded due to missing data when 
completing the SF-MPQ-2 




(n = 55) 
 
Did not return 
Time 2 envelops 
(n = 45) 
Excluded due to 
Missing data 
(n = 7) 
Included in absolute 
(SEM, MDC, BA plots) 
and relative (ICC2,1) 
reliability assessment 
 
          (n = 48)   





















SD pooled = (SD test + SD retest) / 2 
For estimating pooled 
standard deviation (SD 
pooled) from the test and 
retest scores. The SD pooled 
is among the indices 





SEM agreement = Standard Deviation pooled ×√1 − ICC 2,1 
For estimating SEMagreement, 







MDC90individual = 1.64 × √2 × SEM agreement 
For determining the point 
estimate of MDC90individual, 
which is required for 
estimating the confidence 
interval range and the 
MDC90group scores per 




95% CI for MDC90individual  = d ± MDC90individual 
For computing the 90% 
confidence interval range 
for the MDC90individual score 





MDC90group = MDC90individual /√n × 1.64 
For estimating the MDC90 
group score for the entire 
population. 
 
Key: SEMagreement, Standard Error of Measurement (agreement); SDtest, Standard Deviation of test 
scores; SDretest, Standard deviation of retest scores; SDpooled, pooled Standard Deviation; n, sample 
size; CI, confidence interval; MDC90individual, Individual level Minimal Detectable Change at 90% 
CI; MDC90group, Group level Minimal Detectable Change at 90% CI; d, mean difference; ICC2,1, 








TABLE 2: Patient Baseline Characteristic (N = 195) 
Variables N / % 
Age in years (mean + SD) (62 + 17.3) 195/100% 
Shoulder problem  
     Arthroplasty 
     Fracture humeral & others 
     Rotator cuff pathologies 
     Pain 
     Dislocation 
     OA 
     Impingement/bursitis 
 
39 / 20% 
23 / 12% 
48 / 25% 
40 / 21% 
12 / 6% 
18 / 9% 
15 / 8% 
 
Affected Shoulder 
      Right 
      Left 
      Both 
 
 
111 / 56% 
71 / 36% 





103 / 53 % 
92 / 47% 


















TABLE 3: Floor and ceiling effects for test-retest scores of the SF MPQ-2 
total and subscale scores (N= 48) 
Variables Test Retest 
Floor Ceiling Floor Ceiling 
SF-MPQ-2 
Continuous 
7/48 = 14.6% 0/48 = 0% 4/48 = 8.3% 1/48 = 2.1% 
SF-MPQ-2 
Intermittent 
11/48 = 22.9% 0/48 = 0% 15/48 = 31.3% 0/48 = 0% 
SF-MPQ-2 
Affective 
19/48 = 39.6% 1/48 = 2.1% 20/48 = 41.7% 0/48 = 0% 
SF-MPQ-2 
Neuropathic 
14/48 = 29.2% 0/48 = 0% 11/48 = 22.9% 0/48 = 0% 
SF-MPQ-2 
Total 
3/48 = 6.3% 0/48 = 0% 4/48 = 8.3% 0/48 = 0% 



















TABLE 4: Cross-sectional Reliability of the SF-MPQ-2 total and subscale  
scores (N=195) 

















                   Internal consistency (N=195) 
 
Cronbach alpha (95% CI)        Inter-item correlation 
 
 
SF-MPQ-2          
Continuous 
 
0.87 (0.84 – 0.90)                           0.43 – 0.67 
 




0.87 (0.84 – 0.90)                           0.42 – 0.77 
SF-MPQ-2   
Neuropathic 
 
0.85 (0.81 – 0.88)                           0.32 – 0.81 
SF-MPQ-2           
Affective 
 
0.83 (0.79 – 0.87)                           0.44 – 0.78 
SF-MPQ-2                
Total 







TABLE 5: Absolute reliability (agreement parameters) of the SF-MPQ-
2 total and subscale scores (N = 48) 
SF-MPQ-2, Revised Short McGill Pain Questionnaire Version-2; CI, Confidence 
Interval; SEM, Standard Error Measurement; MDC, Minimal Detectable Change. 
SEM (%) and MDC (%) is expressed as the proportion of the obtained SEMagreement or 
MDC90individual of domain represented on the SF-MPQ-2 to the total score of the scale (i.e. 
10 points). 
Variables SEMagreement SEM 
(%) 







0.8 7.8 1.8 (-1.6 – 2.0) 18.1 0.4 
SF-MPQ-2 
Neuropathic 
0.8 7.8 1.8 (-1.7 – 1.9) 18.0 0.4 
SF-MPQ-2 
Intermittent 
1.0 9.9 2.3 (-2.1 – 2.4) 22.9 0.5 
SF-MPQ-2 
Affective 
0.7 7.3 1.7 (-1.5 – 1.8) 16.8 0.4 
SF-MPQ-2        
Total 








TABLE 6: Relative reliability of the SF-MPQ-2 total and subscale Scores (N = 48) 
 
SF-MPQ-2, Revised Short-form McGill Pain Questionnaire Version-2; d, Mean difference (test-retest); SD, Standard deviation; 
CI, Confidence interval; LOA, Limits of Agreement; ICC, Intraclass Correlation Coefficient.  























Single measure ICC2,1 (95% CI) 











-0.14 – 0.51 
 
 
-2.01, 2.38  
 
a
0.90 (0.83 – 0.94) 
 
a





























































































































































































































   
Figure 2 to 6 represent the Bland-Altman Limits of Agreement (LOA) plots between the test and retest scores of the SF-MPQ-2 Total (Fig 
2), Neuropathic (Fig 3), Intermittent (Fig 4), Continuous (Fig 5) and Affective (Fig 6) subscale scores (n = 48). The difference between test-
retest scores is plotted against the mean of test and retest scores for the respective SF-MPQ-2 total and subscales depicted. On each plot, the 
central blue line represents the mean of intra individual differences (d); the upper and lower horizontal broken lines represent the 95% 
LOA. The 95% LOA shows that 95% of the intra individual differences are supposed to within d ± 1.96 SD of mean difference (d). The 







































































In order to use a patient-reported outcome measure (PROM) in research or clinical 
practice, it is important to understand its measurement performance, cost and utility of the 
measure (1–4). The Brief Pain Inventory-Short Form (5,6) and Revised Short McGill Pain 
Questionnaire Version-2 (7) are general-use multidimensional tools recommended for use 
either independently or alongside other measures for comprehensive pain assessment in 
musculoskeletal conditions. This thesis examined existing measurement evidence supporting 
their use in pain-related musculoskeletal conditions. The first thesis manuscript (chapter 2) was 
a systematic review that addressed the quality and content of psychometric evidence 
supporting the BPI-SF and SF-MPQ-2 in MSK conditions. The review identified gaps in the 
literature (8,9) which informed our second thesis manuscript (chapter 3) study aim of 
determining the reproducibility of the SF-MPQ-2. A sample of adults with musculoskeletal 
shoulder pain were then recruited to complete the SF-MPQ-2 in two occasions for us to be able 
to examine reliability and agreement properties (chapter 3). 
The systematic review study (chapter-2) examined the available measurement evidence 
reported for the BPI-SF and SF-MPQ-2 in mixed and specific MSK conditions. The search 
identified 25-articles addressing both tools properties in MSK conditions, however, more than 
half (17-articles) focused of the BPI-SF, perhaps, from its long-time presence in the literature 
(10). Because both tools are general-use PROMs (often applicable in any context for pain 
assessment), studies reporting psychometrics in mixed and specific MSK populations were 






our findings. Despite our inclusion decisions, we were unable to locate studies examining 
psychometric properties for both tools in homogenous upper extremity conditions. The 
findings of our evidence synthesis, based on the COSMIN modified GRADE (11), suggest 
high-quality evidence supports both tools internal consistency and criterion-convergent 
validities in MSK populations. However, the BPI-SF displayed better quality evidence in 
support of its responsiveness, test-retest reliability, known group validity and structural 
validities over that of the SF-MPQ-2. 
Our review identified three important gaps in the literature. First, studies investigating 
content validity, cross-cultural equivalence and MCID/CID were lacking for both tools. 
Second, evidence backing responsiveness and known group validity were mostly flawed (based 
on the COSMIN guidelines). The authors of the included studies did not provide hypotheses 
with specific directions and magnitudes of expected change. Third, the reliability assessment 
for both tools focused mainly on estimating intraclass correlation coefficients and Cronbach 
alpha with no effort towards defining agreement parameters. The first manuscript made 
important recommendations for future research and the second manuscript of this thesis 
addressed some of the gaps in the literature. 
The second research manuscript investigated the reproducibility of the SF-MPQ-2 for 
use among  patients with musculoskeletal shoulder pain. This second research manuscript 
addressed three important gaps in the literature: a) the current dearth in comprehensive 
evidence regarding the reproducibility properties of the SF-MQ-2 in MSK conditions; b) the 
absence of any measurement evidence backing the SF-MPQ-2 in upper extremity MSK 
conditions; c) established the reproducibility of the SF-MPQ-2 for use among patients with 






musculoskeletal shoulder pain was captured and a satisfactory retest interval (3-7days), as 
recommended in the literature, was used. Furthermore, the stability of patients’ responses was 
supported with the concomitant administration of the Global Rating of Change scale. We used 
a wide range of statistical approaches to establish the reliability and agreement properties of 
the SF-MPQ-2 while adhering to existing guidelines (11–13). The second research study 
established acceptable internal consistency, relative reliability (ICC 2,1) and agreement 
parameters (SEM and MDC) for the SF-MPQ-2 use in musculoskeletal shoulder pain, and the 
Bland-Altman method (14,15) confirmed no evidence of systematic bias between retest 
occasions. 
Strengths and Limitations of the Two Manuscripts 
The main strength of the first manuscript was the rigorous steps taken to reach 
conclusions in the review. Two quality assessment processes [COSMIN (1,3,11,13) and 
MacDermid’s methods (16)] were completed to reach conclusions on both tools performance 
in MSK conditions. Furthermore, we presented evidence distinctively for mixed and specific 
MSK population to ensure potential tool users have contextual information on how both tools 
performance in peculiar MSK conditions.  
Two strengths of the second research study were our reliance on established guidelines 
(3,12) and the robustness of our reproducibility analysis. We adhered to established guideline 
instructions in choosing an appropriate retest interval (3-7 days) and the used the Global Rating 
of Change to determine if patients were in stable pain threshold (17). Also, our statistical 
analysis were detailed: we assessed both relative, cross-sectional, and absolute reliability 






ensure confidence in our findings, which influences potential users’ choice for the SF-MPQ-2, 
hence encouraging its clinical applicability. 
However, this thesis has some limitations. First, we compared both tools even though 
they examine slightly different dimensions of pain (BPI-SF = interference; SF-MPQ-2 = 
Quality). Second, making conclusions when using the COSMIN Modified GRADE does not 
equate to a study that directly compares both tools. Third, even though our review identified 
several gaps in the literature, we could only address several issues such as defining the 
reproducibility of the SF-MPQ-2 in MSK population. Therefore, future studies should focus on 
determining the SF-MPQ-2 validity, responsiveness and structural stability using Rasch 
modelling in upper extremity MSK conditions. Finally, our study participants came from a 
regional specialty clinic and the generalizability of our findings is not known. 
Implications 
This thesis has direct implications for research and clinical practice. First, our review 
will serve as a useful resource for potential users of the tools including guideline developers, 
researchers and clinicians to understand the quality, content and scope of measurement 
evidence backing the use of both tools in peculiar and mixed MSK population studies. Second, 
although we have shown that the BPI-SF has better psychometric properties than the SF-MPQ-
2, we suggest that clinicians and researchers should consider the BPI-SF for use, if the 
qualities/characteristics of pain are not the primary aim of patients’ assessment. Third, 
establishing the reproducibility of the SF-MPQ-2 for use among shoulder pain patients means 
researchers and clinicians can be confident that the SF-MPQ-2 yields dependable scores, and 







Our review identified substantial gaps in the literature ranging from methodological 
flaws, absence of evidence in upper extremity MSK populations, and the lack of assessment of 
some measurement properties. Going forward, studies of the psychometric properties of the 
BPI-SF and SF-MPQ-2 in MSK conditions should include:  
a) Standard procedures for further establishing reliability that includes defining agreement 
parameters in mixed and specific MSK conditions, including upper extremity MSK conditions.  
b) A comprehensive assessment of content validity in MSK conditions, bearing in mind that 
each tool captures slightly different concepts of pain (SF-MPQ-2= pain quality; BPI-SF = pain 
interference). The content analysis could include formal cognitive debriefing and ICF linking 
processes. 
c) Assessment of responsiveness, minimal detectable differences, and clinically important 
differences for both tools in MSK conditions is important. In addition, a clear hypothesis with 
direction and expected magnitude should be provided and established anchor/external criterion 
should be utilized. 
d) Determining the known group validity for both tools in MSK conditions is necessary to 
establish the usefulness of the tools. Future studies should employ appropriate statistical 
approaches including the use of ROC analysis, and only anchors/external criterions with 
established psychometric properties should be utilized in such assessment of known group 
validity. 







In conclusion, this thesis adds to the existing pool of literature regarding the 
psychometric and agreement parameters of the Brief Pain Inventory-Short Form and Revised 
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